


British Association of Dermatologists  
**90th Annual Meeting**

**MANCHESTER CENTRAL**  
**6th – 8th July 2010**



Final Programme

**90TH**  
**ANNIVERSARY**  
**MEETING**

**MANCHESTER 2010**



## ELIDEL®: Tough on eczema, not on skin

In mild to moderate eczema where topical steroids can be a problem,<sup>1</sup> ELIDEL® delivers rapid relief from itch.<sup>2</sup> ELIDEL®'s low potential to cause skin atrophy<sup>3</sup> means it can be used on sensitive face and neck areas in both adults and children over two years old.<sup>1</sup>



**UK Abbreviated Prescribing Information. Elidel® 1% cream (pimecrolimus).** Please refer to the ELIDEL® Summary of Product Characteristics for full prescribing information. **Presentation:** Whitish, homogenous cream containing 1% w/w pimecrolimus. **Indications:** Mild or moderate atopic dermatitis (eczema) in patients aged 2 years and over where treatment with topical corticosteroids is either inadvisable or not possible: short-term treatment of signs and symptoms of atopic dermatitis and long-term intermittent treatment for prevention of progression to flares. **Dosage and administration:** ELIDEL cream should be initiated by physicians experienced in the treatment of atopic dermatitis. Discontinue if no improvement after 6 weeks or disease exacerbation. **Adults and children aged 2 years and over:** apply a thin layer of cream to the affected skin twice daily. Rub in gently and completely. Continue until signs and symptoms have resolved, then discontinue. ELIDEL cream may be used on all skin areas, excluding mucous membranes. For long-term intermittent treatment, apply at first signs and symptoms to prevent progression to flares. Continue until signs and symptoms have resolved, then discontinue. Treatment should be intermittent, short-term and not continuous. Emollients can be applied immediately after using ELIDEL cream. **Elderly patients:** clinical studies did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. **Contraindications:** Hypersensitivity to pimecrolimus, other macrolactams or excipients of ELIDEL cream. **Precautions:** May cause mild and transient application site reactions e.g. warmth and/or burning sensation. Avoid contact with eyes and mucous membranes. If accidentally applied to these areas, cream should be thoroughly wiped and/or rinsed off with water. Contains cetyl alcohol, stearyl alcohol and propylene glycol, which may cause skin reactions/irritation. ELIDEL should not be used in patients with congenital or acquired immunodeficiencies or in patients on therapy that causes immunosuppression. Do not use concomitantly with topical corticosteroids or other anti-inflammatory products. Cases of malignancy, including cutaneous and other types of lymphoma, and skin cancers have been reported. However, patients with atopic dermatitis treated with ELIDEL have not been found to have significant systemic pimecrolimus levels. Long-term effect on the local skin immune response and on the incidence of skin malignancies is unknown. ELIDEL should not be applied to potentially malignant or pre-malignant skin lesions, or to areas affected by acute cutaneous viral infections (herpes simplex, chicken pox). Clear infections at treatment sites before application. Increased risk of herpes simplex virus skin infection and eczema herpeticum.

If herpes simplex virus skin infection develops, discontinued ELIDEL until the infection has cleared. Increased risk of skin bacterial infections (impetigo) in patients with severe atopic dermatitis. Not recommended in patients with erythroderma or Netherton's syndrome. Do not apply under occlusive dressings. Not recommended during pregnancy or breast feeding. In patients with extensive disease, administer vaccinations during treatment-free intervals. Avoid excessive exposure of skin to ultraviolet light. Avoid therapy with PUVA, UVA or UVB during treatment. **Undesirable effects:** Application site reactions reported by 19% of ELIDEL patients and 16% of patients in the control groups. These reactions generally occurred early in treatment, were mild/moderate and of short duration. **Very common** ( $\geq 1/10$ ): application site burning. **Common** ( $\geq 1/100, < 1/10$ ): application site reactions (irritation, pruritus, erythema), skin infections (folliculitis). **Uncommon** ( $\geq 1/1,000, < 1/100$ ): furuncle, impetigo, herpes simplex, herpes simplex dermatitis (eczema herpeticum), molluscum contagiosum, skin papilloma, application site disorders such as rash, pain, paraesthesia, desquamation, dryness, oedema, and condition aggravated. **Quantities and basic NHS price (excl. VAT):** 30g tube, £19.69; 60g tube, £37.41; 100g tube, £59.07. **Marketing authorisation number:** PL 0010/0659. © denotes registered trademark. **Legal category:** POM. **Full prescribing information is available on request from:** Novartis Pharmaceuticals UK Ltd., Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR. Telephone (01276) 698370. Fax (01276) 698449. **Date of preparation:** 10th September 2007.

**Adverse events should be reported. Reporting forms and information can be found at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk). Adverse events should also be reported to Novartis (01276) 698370**

#### References:

1. ELIDEL® SmPC. Novartis Pharmaceuticals UK Limited.
2. Meurer M, Fartasch M, Albrecht G, et al. *Dermatol* 2004;208:365-372.
3. Queille-Roussel C, Paul C, Duteil L, et al. *Br J Dermatol* 2001;144:507-513.

Date of preparation: January 2009.  
ELI09-001

# INDEX

|   | <b>PAGE NUMBER</b> |
|---|--------------------|
| Accommodation                             | 6 - 7              |
| Accompanying persons                      | 8                  |
| Additional meetings                       | 48                 |
| Badges                                    | 8                  |
| Banking                                   | 8                  |
| Business Services                         | 8                  |
| Catering                                  | 8                  |
| Certificates of attendance                | 8                  |
| Childminding / Babysitting                | 8                  |
| Cloakroom                                 | 8                  |
| Committee meetings                        | 15                 |
| Continuing Professional Development (CPD) | 8                  |
| Delegate bags                             | 8                  |
| Evaluation form                           | 9                  |
| Exhibition                                | 9                  |
| Exhibition quiz                           | 9                  |
| Exhibition plan                           | 13                 |
| First aid                                 | 9                  |
| Map of Manchester                         | 59                 |
| Meetings Calendar                         | 60                 |
| Messages                                  | 9                  |
| Organising Committees                     | 4                  |
| Parking                                   | 9                  |
| Patient support groups                    | 9                  |
| Payment of registration fees              | 10                 |
| Poster exhibition                         | 10                 |
| Posters                                   | 49 - 55            |
| Programme index                           | 16                 |
| Registration desk                         | 10                 |
| Restaurants                               | 10                 |
| Satellite Symposia                        | 56 - 58            |
| Social events                             | 14                 |
| Speaker preview                           | 10                 |
| Special interest groups                   | 10                 |
| Sports activities                         | 14                 |
| Taxis                                     | 11                 |
| Transport – to and from Manchester        | 11                 |
| Venue Plan                                | 12                 |
| Welcome to Manchester                     | 5                  |

|  | <b>PAGE NUMBER</b> |
|--|--------------------|
| <b>MONDAY OVERVIEW</b> <span style="float: right;"><b>17</b></span>    |                    |
| DermSchool   | 18                 |
| Trainee pre-conference session   | 19                 |
| SAS Session  | 20                 |
| <b>TUESDAY OVERVIEW</b> <span style="float: right;"><b>21</b></span>   |                    |
| CPCs –Joint BAD / BSD  | 22 - 23            |
| Plenary Session  | 23 - 24            |
| British Society of Cutaneous Allergy (BSCA)                            | 25 - 26            |
| British Society for Paediatric Dermatology (pm)                        | 27 - 28            |
| Historical   | 29                 |
| British Society for Dermatopathology (BSD)                             | 30 - 31            |
| <b>WEDNESDAY OVERVIEW</b> <span style="float: right;"><b>33</b></span> |                    |
| Plenary session am   | 34                 |
| Plenary session – Medical Dermatology                                  | 35                 |
| BAD and BDNG Joint Meeting   | 36                 |
| British Society for Dermatological Surgery (BSDS)                      | 37 - 39            |
| British Photodermatology Group (BPG)                                   | 40 - 41            |
| <b>THURSDAY OVERVIEW</b> <span style="float: right;"><b>43</b></span>  |                    |
| Plenary Session Professor's & Registrars' forum                        | 44 - 45            |
| CPD update   | 45 - 46            |
| <b>KEYNOTE LECTURES</b>  |                    |
| <b>Tuesday</b>   |                    |
| Professor Frank Nestle   | 24                 |
| Sir Leszek Borysiewicz   | 24                 |
| <b>Wednesday</b>   |                    |
| Dr Jean Bologna  | 34                 |
| <b>Thursday</b>  |                    |
| Dr Joseph Jorizzo  | 45                 |
| Professor Sarah Thomas   | 46                 |

## CONFERENCE & EVENT SERVICES

Mr Christopher Garrett – Conference & Event Services Manager  
Mrs Marie Elwér – Finance and Conference Administrator  
Miss Jenna Sanders – Events Coordinator  
Miss Sally-Ann Koomson – Marketing & Events Coordinator

British Association of Dermatologists  
4 Fitzroy Square  
London W1T 5HQ  
Tel: +44 (0)20 7391 6358  
Fax: +44 (0)20 7388 0487  
Email: [conference@bad.org.uk](mailto:conference@bad.org.uk)

## ORGANISING COMMITTEE

Dr Stephen Jones – Chair  
Professor Alex Anstey  
Miss Marilyn Benham  
Dr David J Eedy  
Mr Chris Garrett  
Dr Mark Goodfield  
Mrs Catherine Hanaway  
Professor Eugene Healy  
Dr Glenda Hill  
Dr Laura Proudfoot  
Dr Jane Sterling

## SCIENTIFIC COMMITTEE

Dr Stephen Jones – Chair  
Dr Alison Bedlow  
Dr Claire Fuller  
Dr Mark Goodfield  
Dr James Langtry  
Dr Rob Lister  
Professor Edel O'Toole  
Dr Jane Sterling  
Dr Saleem Taibjee  
Dr Mike Tidman  
Dr Maureen Walsh

## JUDGING COMMITTEE

Dr Mike Arden-Jones - Chair  
Dr Sara Brown  
Dr Richard Goodwin  
Dr Philip Hampton  
Dr Jenny Hughes  
Dr Katie Lacy  
Dr Richard Logan  
Dr Richard Meyrick-Thomas  
Dr Kate Orteu  
Dr John Reed

## ACKNOWLEDGEMENTS

The British Association of Dermatologists gratefully acknowledges the contribution of the many exhibitors & sponsors whose attendance has helped make the meeting possible.

# A WARM WELCOME TO MANCHESTER 2010

The 90th Annual Meeting of the BAD will see us return to the city of Manchester, the venue for the 2006 meeting. The Manchester Central Convention Complex (MCCC) has undergone a re-branding exercise and also significant renovation work since 2006 to keep it at the cutting edge of conference centre design. The venue now has excellent facilities, including a spacious auditorium for plenary sessions as well as ample space for exhibitors and for meetings of every conceivable size.



Situated within the city centre, the MCCC is within easy reach of hotels, restaurants and the venues for social events to be staged during the week. As such, it promises to be an ideal base for what promises to be a memorable 90th Meeting.

## Scientific Programme

In response to member's feedback, the meeting this year has been condensed into three full days with the final CPD session now taking place on the Thursday afternoon. Despite this, the content of the meeting remains first class with all of our usual guest speakers and plenary sessions.

The opening Tuesday afternoon plenary session will see Professor Frank Nestle from London talk on 'From genes to function and therapy in Psoriasis'. He will be followed later that afternoon by Professor Sir Leszek Borysiewicz, Chief Executive of the Medical Research Council (MRC) speaking on the topic of Research. Wednesday's programme will incorporate Dr Jean Bolognia of New Haven, USA addressing the audience with an 'Update on cutaneous side effects of chemotherapy'. The final guest lecture will come from Professor Sarah Thomas on Thursday afternoon talking on 'Current thinking in medical education'.

The Arthur Rook Oration this year will be delivered by Dr Joseph Jorizzo, from North Carolina, USA, presenting on 'Neutrophilic vascular reactions' and will occur after the Professors and Registrars forum on the Thursday morning which this year features Professors Chris Griffiths, Alex Anstey and Edel O'Toole.

*Medical Dermatology* continues to feature strongly in the programme with a dedicated session on Wednesday afternoon. We have Satellite Symposia each day and will continue with the poster viewing slot before the AGM on Wednesday morning. The meeting will finish with the popular CPD session on Thursday afternoon.

Our colleagues from the British Dermatological Nursing Group (BDNG) will have a busy academic programme in parallel with ours and will join us for the Joint Session on Wednesday afternoon.


Detailed times can be found in this brochure.

## Social Programme

The condensed format of the meeting has meant some changes to the usual social programme. The Welcome Reception will be held within the Exhibition hall at the MCCC on the Tuesday evening offering a unique chance for all attendees and exhibitors to meet on the opening evening of the Annual Meeting. This format has proved popular for many years at major International meetings and lends itself to a great social occasion. The reception will begin after the final session finishes at 18:00 and will leave time for attendees to attend other functions or dine socially afterwards.

The Annual Dinner will be held at the Manchester Town Hall on the Wednesday evening. Completed in 1887, this most impressive neo-Gothic building is acknowledged as a masterpiece in its own right. Places will be limited so book early to avoid disappointment.

Enjoy the meeting!



**Stephen Jones**  
Clinical Vice President (2008-2010)

# ACCOMMODATION

## HOTEL RESERVATION FORM

### The 90th Annual Meeting of the British Association of Dermatologists / The 20th Annual Meeting of the British Dermatological Nursing Group 2010

Marketing Manchester is the official hotel booking service for:  
**The 90th Annual Meeting of the British Association of Dermatologists /  
 The 20th Annual Meeting of the British Dermatological Nursing Group 2010**  
 Tuesday 6th - Thursday 8th July 2010, Manchester Central

To book online, please visit: [www.conferencebookings.co.uk](http://www.conferencebookings.co.uk) and use the Event Reference: **MNCBAD2010**

Please return to: Carver's Warehouse, 77 Dale Street, Manchester, M1 2HG

Telephone: **0871 2262 467**

If you have any queries please e-mail [abs@marketing-manchester.co.uk](mailto:abs@marketing-manchester.co.uk)

The application deadline is **FRIDAY 18 JUNE 2010**. If you wish to apply for accommodation after this deadline has expired, Marketing Manchester will endeavour to meet your requirements, but requests will be purely on an ad hoc basis and preferred accommodation and rates cannot be guaranteed.

#### BLOCK CAPITALS PLEASE

\* Entry required

|                 |                 |           |
|-----------------|-----------------|-----------|
| TITLE*          | SURNAME*        | FORENAME* |
| ORGANISATION*   |                 |           |
| ADDRESS*        |                 |           |
|                 |                 |           |
| POSTCODE        | E-MAIL*         |           |
| TELEPHONE       | FAX             |           |
| ARRIVAL DATE*   | DEPARTURE DATE* |           |
| NO. OF EVENINGS | NO. OF PERSONS  |           |

Single Occupancy (1 person)  Double Occupancy (2 persons)  Twin Occupancy (2 persons)

(A Double room for sole occupancy cannot be guaranteed)

PLEASE INDICATE ANY SPECIAL REQUIREMENTS (Proforma Invoice etc)

Please tick if you require dinner

FURTHER INFORMATION (Please indicate your preferred hotels from the selection attached)

|            |
|------------|
| 1st choice |
| 2nd choice |
| 3rd choice |

#### Guarantee ONLY

|                        |                 |             |
|------------------------|-----------------|-------------|
| Credit/debit card type | Valid from date | Expiry date |
| Card no                | Name on card    |             |

Please indicate here if you do **NOT** wish to remain on the Marketing Manchester database

I have read and acknowledge the terms and conditions  (please see overleaf)

|                               |      |
|-------------------------------|------|
| Signed (authorised signatory) | Date |
|-------------------------------|------|

# ACCOMMODATION

## The 90th Annual Meeting of the British Association of Dermatologists / The 20th Annual Meeting of the British Dermatological Nursing Group 2010

Tuesday 6th - Thursday 8th July 2010, Manchester Central



Map not to scale

| Hotel  | Star Rating | Car Park | Single Rate B&B | Double Rate B&B |
|--|-------------|----------|-----------------|-----------------|
| 1 Arora International                                  | 4           | NCP      | 99.00           | 109.00          |
| 2 Atrium by Bridgestreet                               | 4           | NCP      | 82.00           | 92.00           |
| 3 Britannia Manchester                                 | 3           | NCP      | 65.00           | 85.00           |
| 4 City Inn Manchester                                  | 4           | NCP      | 99.00           | 109.00          |
| 5 Crowne Plaza Manchester                              | 4           | NCP      | 125.00          | 135.00          |
| 6 Etap Hotel (not city centre)                         | n/a         | NCP      | 40.00RO         | 40.00RO         |
| 7 Days Hotel   | 3           | NCP      | 78.50           | 88.50           |
| 8 Hilton Deansgate                                     | 4           | NCP      | 139.00          | 149.00          |
| 9 Jurys Inn Manchester                                 | 3           | NCP      | 105.00          | 115.00          |
| 10 Macdonald Manchester                                | 4           | NCP      | 115.00          | 125.00          |
| 11 Novotel Manchester Centre                           | 3           | NCP      | 89.00           | 99.00           |
| 12 Park Inn (not city centre)                          | 4           | NCP      | 110             | 120             |
| 13 Premier Inn Manchester Central                      | n/a         | NCP      | 79.95           | 87.90           |
| 14 Radisson Edwardian                                  | 5           | NCP      | 145             | 155             |
| 15 Ramada Piccadilly                                   | 3           | NCP      | 80              | 90              |
| 16 The Castlefield Hotel                               | 3           | NCP      | 85              | 91              |
| 17 The Lowry   | 5           | NCP      | 150.00          | 160.00          |
| 18 The Midland Hotel                                   | 4           | NCP      | 135.00          | 145.00          |
| 19 The Palace Hotel                                    | 4           | NCP      | 110.00          | 120.00          |
| 20 The Place Apartments                                | 4           | NCP      | 125.00RO        | 125.00RO        |
| 21 The Thistle   | 3           | NCP      | 100.00          | 110.00          |
| 22 The Weston Hall                                     | Student     | NCP      | 39.50           | n/a             |
| <b>Total Number of City Centre Rooms on Allocation</b> |             |          | <b>1190</b>     |                 |

BB = Bed & Breakfast. RO = Room Only (excludes breakfast). T/A = Travel Accommodation. INC = Room rate inclusive of VAT.  
Room Rate is Per Night at Single Rate for 1 Person and Double Rate for 2 Persons. VAT = Value Added Tax @ 17.5%.

### Conditions & Liabilities

- The rates noted are Per Room Per Night and include private facilities WC with bath and/shower, full English Breakfast (Unless otherwise stated) and VAT at 17.5%
- Accommodation will be allocated on a first come, first served basis, if your preferred accommodation is not available, a similar standard of accommodation will be allocated from your choices.
- When a delegate completes and returns a "paper" reservations form to Marketing Manchester and the delegate receives email confirmation this then a legally binding agreement.
- Marketing Manchester will send you confirmation of your reservation via email, please ensure you supply an email address to receive your confirmation promptly
- Marketing Manchester acts only as an agent for hotels and other accommodation providers and does not contract a principle. Accordingly, they are not liable for any loss or damage due to or arising from any acts or omissions of persons, firms or companies for whom they act as agents.
- The Bureau shall not be liable to any extent in the event of delay or failure in providing or procuring any services or facilities due to any cause beyond the proper control.
- The Bureau acts as an intermediary in securing accommodation for this event and cannot accept any responsibility for standards of the accommodation providers.
- When Marketing Manchester receive a completed reservation form from the delegate concerned and email confirmation and been received by the delegate from Marketing Manchester - This confirms the delegate has accepted responsibility of the reservation made on their behalf and they are liable for any charges that may arise from the reservation.
- Your credit card details are not issued to the hotel via Marketing Manchester; they are ONLY a guarantee method not a payment method. Any other additional services are not included in your reservation, so any further charges incurred are payable by the individual directly to the hotel concerned.
- The balance of hotel accounts must be settled on arrival/departure unless alternative arrangements have been agreed in advance DIRECT with the hotel concerned.
- Marketing Manchester can request a Pro Forma Invoice on behalf of a person(s) to be issued to you for settlement of payment, but are not liable if the hotel does not issue this to the requesting person(s).
- Individuals must advise Marketing Manchester of cancellations/amendment via either email (abs@marketing-manchester) or by fax (0161 907 3723) not less than 24 hours prior to your arrival date. In the event of the late cancellation, the individual will be liable for the first nights accommodation.

## ACCOMPANYING PERSONS

If you would like to book a place on either of the accompanying persons' tours please complete the relevant section of the registration form.

### Tuesday 6th July, 14:00 – 17:00

Fee – £20

#### John Rylands Library and afternoon tea

This masterpiece of Victorian Gothic architecture looks more like a castle or cathedral and is a memorial by a devoted wife to her husband, John Rylands, one of Manchester's most successful cotton industrialists. The interior and exterior architecture is beautiful, and exhibitions include illuminated medieval manuscripts. This will be followed by afternoon tea and a visit to either the Town Hall or Art Gallery.

### Wednesday 7th July, 09:30 – 17:00

Fee – £40 (lunch and tour included)

#### Tatton Park

Tatton Park is one of the UK's most complete historic estates and is set in acres of rural grounds. Enjoy a tour of the Mansion House followed by Lunch in Lord Egerton's apartment which overlooks the gardens and extensive countryside. Then meet the Head Gardner at the property for a tour of the gardens.

**We regret that neither accompanying persons nor children/babies are permitted entrance to the exhibition areas.**

## BADGES

Conference badges will be handed to delegates on registration. For security purposes name badges must be worn at all times throughout the meeting. In the event that you lose your badge, a replacement must be obtained at the registration desk immediately.

## BANKING

Aleefs Newsagent (2min walk) next door to Starbucks straight on out of the front entrance.  
Barclays cash point only (5min walk) located on Deansgate opposite Sainsbury's.  
Barclays Bank (5-8min walk) Moseley Street.

## BUSINESS SERVICES

Photocopying (10p per copy black and white and 50p per colour A4) faxes and a telephone line will be available in the organisers office.

The phone number for the organisers office is 0161 834 3339 and the fax number is 0161 834 8622.

## CATERING

Lunch and all scheduled refreshment breaks will be served from designated points in the exhibition hall of the Manchester Central Convention Complex. If

the nearest catering point is not open, staff will direct you to the next most convenient point.

## CERTIFICATES OF ATTENDANCE

Certificates of attendance will automatically be sent to all attendees after the meeting.

## CHILDMINDING/ BABYSITTING

There will be no crèche facilities at the meeting. Please approach your hotel directly for a babysitting service or to make alternative child care arrangements. Please note that babies and children cannot be admitted to the exhibition areas or social events.

There is a crèche facility at the town hall. The contact details are:

St. Peters Children's Centre  
Myriam Bradshaw  
0161 234 3246

## CLOAKROOM

The cloakroom will be located in the Foyer at the Manchester Central Convention Complex. There will be no charge. Guests will also be able to store luggage on the day of departure.

## COMMITTEE MEETINGS

A programme of the scheduled committee meetings can be found on page 15.

## CONTINUING PROFESSIONAL DEVELOPMENT CREDITS (CPD)

This event will be approved for External credit for the CPD Scheme of the Federation of Royal Colleges of Physicians of the UK. Physicians should record their credits in their diaries, in accordance with the current RCP recommendations. Participants should only record the number of hours they attended.

## DELEGATE BAGS

The Conference & Events Department is aiming to limit the impact the Annual Meeting has upon the environment.

Conferences and exhibitions provide a huge amount of waste and this year we aim to continue to implement measures to improve this.





Following delegate feedback from last years meeting delegates will be provided with a generic delegate bag (as illustrated). This bag is made from recycled plastic bottles and has the BAD Logo on the side.

We have made a decision not to include a sponsor, date or annual meeting destination. This will enable you to reuse the bag for other annual meetings as well as other BAD meetings. We hope this will become your BAD 'Bag for Life'.

At future annual meetings we will have a stock supply of these bags but would encourage delegates to bring their own.

## EVALUATION FORM

This year's evaluation form will be on-line and all attendees will be sent a link after the meeting.

Thank you in advance for taking the time to complete it, as it is an invaluable tool for us in organising future meetings.

## EXHIBITION

The exhibition will be located in the Central 2 Hall of Manchester Central and will be open at the following times:

|                    |               |
|--------------------|---------------|
| Tuesday 6th July   | 10:00 – 19:30 |
| Wednesday 7th July | 08:30 – 17:30 |
| Thursday 8th July  | 08:30 – 14:30 |

## EXHIBITION QUIZ

Exhibition quiz forms will be included in delegate bags. To participate in the quiz, delegates must visit each participating exhibitor and answer a simple question. Participants must also obtain 4 answers from the patient support groups, please note you only need 4 from any of the Patient Support Groups present over the duration of the meeting. All completed quiz forms must be returned to the registration desk by 14:00 on Thursday 8th July. The prizes will be announced after the meeting.

## EXHIBITORS

Please see page 13 for a full list of exhibitors and an exhibition plan.

## FIRST AID

The First Aid Suite is situated by the exhibitor storage area in the exhibition hall and will be staffed by Manchester Central. The first aid mobile phone number is 07527 254221.

## MESSAGES

A delegate notice board will be situated adjacent to the registration desk, where all delegates' messages will be displayed.

## PARKING

Once you have travelled into the city by car, then the best place to park is the NCP car park on site at Manchester Central. It is open 24 hours and the address details for sat nav are: Lower Mosley Street, Manchester, M2 3GX.

For more information on NCP car parks in Manchester, visit [www.ncp.co.uk](http://www.ncp.co.uk) or telephone 0845 050 7080.

## PATIENT SUPPORT GROUPS

The following patient support groups will be represented at the meeting and will have stands in the exhibition hall:

### Tuesday 6th July, Wednesday 7th July Only

British Porphyria Association  
Dystrophic Epidermolysis Bullosa Research Association (DebRA)  
Gorlin Syndrome Group

### Tuesday 6th July, Wednesday 7th July, Thursday 8th July

Alopecia UK  
Dowling Club  
Ichthyosis Support Group  
Neurofibromatosis Association  
NHS Evidence – skin disorders  
Nodular Prurigo UK  
Psoriasis and Psoriatic Arthritis Alliance  
Psoriasis Scotland Arthritis Link Volunteers (PSALV)  
Skin Camouflage Network  
The British Association of Skin Camouflage  
The British Red Cross  
The Hyperhidrosis Support Group  
The Lymphoedema Support Network  
The Psoriasis Association  
UK Dermatology Clinical Trials Network  
Vulval Pain Society

### Wednesday 7th July, Thursday 8th July Only

Latex Allergy Support Group  
Scleroderma Society  
Vitiligo Society  
XP Support Group

### In addition, the following groups will have stands within the exhibition area:

BADBIR  
British Dermatological Nursing Group  
British Journal of Dermatology / CED  
British Skin Foundation  
Community Dermatology & IFD  
Historical Collection  
e-Dermatology

## PAYMENT OF REGISTRATION FEES

We would prefer delegates to pay by cheque (pounds sterling drawn on a UK bank only or by sterling bank draft) made payable to the 'British Association of Dermatologists'. Cheques in other currencies cannot be accepted. Alternatively, delegates may pay by credit card and this is encouraged for overseas delegates. Please note that we only accept MasterCard and Visa. **American Express cannot be accepted.**

## POSTER EXHIBITION

The poster exhibition will be located within Central 2 of Manchester Central. The posters will be numbered and a list is provided at the back of this programme.

Posters should measure a maximum of 1.5m high x 1m wide (portrait) and must be mounted with Velcro. Presenters will be able to mount their posters from 10:00 on Tues 6th July. Posters should not be removed until 14:00 on Thursday 8th July. Please note that the British Association of Dermatologists cannot be held responsible for any loss or damage to a poster presented during the Annual Meeting.

## REGISTRATION DESK

Upon arrival please make your way to the registration desk located in the Manchester Central Foyer. It will be staffed by the BAD team during the following hours:

Monday 5th July                      08:30 – 18:00  
 Tues 6th - Thurs 8th July      07:30 – 18:00

## RESTAURANTS

Below are the details of a few locally recommended restaurants.

**Beluga**                                      Tel: 0845 058 2604  
**(Modern European)**  
[www.belugaonline.co.uk](http://www.belugaonline.co.uk)

**Opus One Restaurant**      Tel: 0845 058 2654  
 Radisson Edwardian

**Tiger Tiger (Grill)**                      Tel: 0845 058 2630

**The Printworks**  
[www.tigertiger.co.uk](http://www.tigertiger.co.uk)

**Old Orleans Cocktail Bar & Grill**      Tel: 0845 058 2653

**The Printworks**  
[www.oldorleans.com](http://www.oldorleans.com)

### Bar 38

Tel: 0161 835 3076

Peter Street

[www.bar38manchester.co.uk](http://www.bar38manchester.co.uk)

## SATELLITE SYMPOSIA

The following companies will be holding satellite symposia at the meeting:

### Tues 6th July

13:15 – 14:15

**Abbott**

13:15 – 14:15

**Pfizer**

### Wednesday 7th July

13:15 – 14:15

**Janssen-Cilag**

13:15 – 14:15

**La Roche-Posay**

### Thursday 8th July

13:15 – 14:15

**Schering Plough**

## SOCIAL EVENTS

Please see Social Programme (Page 14).

## SPEAKER PREVIEW

Speaker preview will be located in Central Room 4 in the foyer at Manchester Central, please ask at the registration desk for directions. All presenters must take their presentations to speaker preview at least two hours prior to their presentation. Data projection (PowerPoint) will be available.

## SPECIAL INTEREST GROUPS

The following Special Interest Groups will hold their meetings during the week of the conference. All special interest group meetings will take place in Manchester. Their full programmes are featured at the back of each days full programme.

### Tues 6th July

British Society of Cutaneous Allergy  
 09:00 – 12:30 (Page 25 – 28)

British Society for Paediatric Dermatology  
 09:00 – 12:45 (Page 27 – 28)

Historical  
 11:00 – 12:00 (Page 29)

British Society for Dermatopathology  
 15:00 – 18:00 (Page 30 - 31)

### Wednesday 7th July

British Society for Dermatological Surgery  
 14:30 – 18:00 (Page 37 – 39)

British Photodermatology Group  
 14:30 – 18:00 (Page 40 – 41)

## TAXIS

- **Radio Cars Manchester** 0161 236 8033
- **Mantax Taxis Ltd** 0161 230 3333
- **Manchester Minibus Taxis** 0161 850 0568
- **Manchester Cars** 0161 237 3383
- **Manchester Limousine Service** 0161 49 20 307

## TRANSPORT

- IN AND AROUND MANCHESTER
- TO AND FROM MANCHESTER CENTRAL

[www.manchestercentral.co.uk/getting-here](http://www.manchestercentral.co.uk/getting-here)

Manchester Central is in the heart of Manchester city centre in the North West of England. Located in the centre of the UK, the city is served by strong road, rail and air links, making it an easily accessible location for visitors from all over the world.

### By road

Manchester is at the heart of the Northwest’s motorway network with easy access from all directions onto the M60, the city’s orbital motorway. Once on the M60 exit at Junction 12 and join the M602 signposted towards the city centre. Follow the A57 straight on from the end of the M602 passing under a railway bridge before taking the left hand exit to merge onto the A56 Bridgewater Way. Turn right onto Whitworth Street West at Deansgate station and then turn left onto Albion Street. The entrance to the Manchester Central Car Park is through the next set of traffic lights on the left, opposite The Bridgewater Hall.

If you are using sat nav, type in M2 3GX which will take you to the car park at Manchester Central.

The following links may be useful in helping to plan your journey by car:

- [www.theaa.com](http://www.theaa.com)
- [www.highways.gov.uk](http://www.highways.gov.uk)

### By rail

Manchester has direct rail connections to all major UK cities – London is just over two hours away by train. Services come into the city at either Piccadilly or Victoria station, both of which connect to Manchester’s Metrolink light-rail system which provides easy access to all parts of the city centre. Take the Metrolink from either Piccadilly or Victoria (in the Altrincham or Eccles direction) and alight at St Peter’s Square, which is within a 5-minute walk of Manchester Central. You can also take advantage of

the free Metroshuttle bus that travels between the two stations across the city centre.

For information on train services to Manchester, please use the following links:

[www.virgintrains.co.uk](http://www.virgintrains.co.uk)

[www.nationalrail.co.uk](http://www.nationalrail.co.uk)

### By air

Manchester airport is a major international air traffic hub with frequent scheduled flights to the majority of key UK, European and international destinations. It is 9 miles (14.5km) outside the city centre, taking approximately 25 minutes by taxi, or alternatively there is a direct half-hourly express rail service to the city centre that takes approximately 20 minutes.

More information on services to Manchester airport can be found at [www.manchesterairport.co.uk](http://www.manchesterairport.co.uk).

### VENUE

Manchester Central

Petersfield

Manchester M2 3GX


Tel +44 (0)161 834 2700

Fax +44 (0)161 833 3168

<http://www.manchestercentral.co.uk>

# Manchester Central Venue Plan

VENUE PLAN



# Exhibition Plan



| Stand Number | Company                                   | Stand Number | Company   |
|--------------|---|--------------|---|
| E15          | 4s Information Systems                    | PSG 20       | Alopecia UK   |
| B7           | Abbott                                    | PSG 9        | British Porphyria Association                                 |
| E20          | Academic Dermatology                      | PSG 23       | British Red Cross   |
| D20          | Activa Healthcare                         | PSG 8        | Dystrophic Epidermolysis Bullosa Research Association (DeBRA) |
| D19          | Alliance Pharmaceuticals Ltd              | PSG 7        | Gorlin Syndrome Group   |
| C1           | Almirall                                  | PSG 10       | Ichthyosis Support Group                                      |
| B1           | Astellas Pharma Ltd                       | PSG 4        | Latex Allergy Support Group                                   |
| E21          | Athrodax Healthcare International Limited | PSG 12       | Neurofibromatosis Association                                 |
| E14          | BAD Historical Display                    | PSG 15       | NHS Evidence - skin disorders                                 |
| E19          | BADBIR                                    | PSG 21       | Nodular Prurigo UK  |
| B15          | Basilea Pharmaceuticals Ltd               | PSG 11       | Psoriasis and Psoriatic Arthritis Alliance                    |
| E24          | Beiersdorf                                | PSG 2        | Psoriasis Scotland Arthritis Link Volunteers (PSALV)          |
| E13          | BJD & CED                                 | PSG19        | Scleroderma Society   |
| E10          | British Skin Foundation                   | PSG 1        | Skin Camouflage Network                                       |
| E4           | Brymill Cryogenic Systems (UK) Ltd        | PSG 18       | The British Association of Skin Camouflage                    |
| D6           | Candela UK                                | PSG 22       | The Dowling Club  |
| D15          | Cephalon UK Ltd                           | PSG 16       | The Hyperhidrosis Support Group                               |
| D16          | Clarisonic                                | PSG 13       | The Lymphoedema Support Network                               |
| D4           | CliniMed Ltd                              | PSG 14       | The Psoriasis Association                                     |
| E6           | Clinique Laboratories LLC                 | PSG 5        | UK Dermatology Clinical Trials Network                        |
| E12          | Community Dermatology & IFD               | PSG 6        | Vitiligo Society  |
| D13          | Cosmetique Active                         | PSG 17       | Vulval Pain Society   |
| D10          | Cranaeg Healthcare Ltd                    | PSG 3        | XP Support Group  |
| E2           | Crawford Pharmaceuticals Ltd              |              |   |
| C5           | Croda Europe Ltd                          |              |   |
| C15          | Derma UK Ltd                              |              |   |
| C13          | Dermal Laboratories Ltd                   |              |   |
| E23          | Dexcel Pharma Ltd                         |              |   |
| C3           | Diagenics Ltd                             |              |   |
| A7           | e-learning for healthcare                 |              |   |
| D14          | Esperé Healthcare Ltd                     |              |   |
| D9           | Forest Laboratories UK Ltd                |              |   |
| A2           | Galderma (UK) Ltd                         |              |   |
| C16          | Healthcare at Home                        |              |   |
| C9           | Janssen-Cilag Ltd                         |              |   |
| C8           | Johnson & Johnson                         |              |   |
| E22          | Kensington Consultants                    |              |   |
| A1           | LEO Pharma                                |              |   |
| E3           | Lynton                                    |              |   |
| A4           | M & A Pharmachem Ltd                      |              |   |
| E18          | MA Healthcare                             |              |   |
| E25          | Meda Pharmaceuticals Ltd                  |              |   |
| A3           | Michelson Diagnostics Ltd                 |              |   |
| E11          | Mjms Dermatology                          |              |   |
| D16          | Molinycke Health Care                     |              |   |
| B8           | Pfizer                                    |              |   |
| E8           | Phadia Ltd                                |              |   |
| C7           | Reckitt Benckiser                         |              |   |
| B9           | Schering-Plough Ltd                       |              |   |
| D2           | Schuco International (London) Ltd         |              |   |
| D17          | Shire Pharmaceuticals Ltd                 |              |   |
| D11          | Skin Brands Limited                       |              |   |
| C6           | STD Pharmaceuticals                       |              |   |
| D7           | Stiefel, a GSK company                    |              |   |
| E9           | Synergy Health                            |              |   |
| E17          | Therakos                                  |              |   |
| D5           | Thornton & Ross Ltd                       |              |   |
| D1           | Typharm Dermatology                       |              |   |
| A5           | Uvistat                                   |              |   |
| C4           | Wiley-Blackwell                           |              |   |
| A6           | Wipress Ltd                               |              |   |

90th Annual meeting of the British Association of Dermatologists  
20th Annual meeting of the British Dermatological Nursing Group  
6th - 8th July 2010

# EXHIBITION PLAN

## SOCIAL EVENTS

### WELCOME RECEPTION

**Tuesday 6th July 18:00 – 19:30**  
**Manchester Central**

The Welcome Reception will be held within the Exhibition hall on the Manchester Central venue, offering a unique chance for all attendees and exhibitors to meet on the opening evening of the Annual Meeting. This format has proved popular for many years at major International meetings and lends itself to a great social occasion. Drinks and canapés will be served after the final session finishes at 18:00 and will leave time for attendees to dine afterwards.

### ANNUAL DINNER

**Wednesday 7th July 19:30**  
**Manchester Town Hall**

The Annual Dinner will be held at the Manchester Town Hall. Completed in 1887, this most impressive neo-Gothic building cost a million pounds and is acknowledged as a masterpiece in its own right. It rises as a Victorian edifice - a monument to the civic pride of the city fathers, reaching 286 feet above Albert Square below. Places will be limited so book early to avoid disappointment.



*Manchester Town Hall  
 Annual Dinner venue*

## SPORTS ACTIVITIES

### Tuesday 6th July

All sports events will be held at venues in and around the city on Tuesday evening. The departure point for all events will be from outside the Manchester Central Convention Centre.

### **Bowers-Sneddon-Harman Sailing Competition – 18:00, meet by registration at 17:30**

The sailing competition will take place at Elton Sailing Club on the Elton Reservoir in Bury. Limited places will be available and people should bring warm layers and waterproofs. Full details of the event will be sent following registration.

### **Dowling – McCaw Golf Cup – 15:00**

A local golf club will host this event. Please note that Green fees will be charged per person. Full details of the event will be sent following registration.

### **Five-a-side Football – 18:00, meet by registration at 17:30**

The competition will be held at Powerleague, Manchester Central. The competition is open to everyone, members, non-members, guests and exhibitors. You may apply as a team or individually.

### **Ive Piscatorial (Fishing) Competition**

Further details of the event will be sent following registration.

### **Tennis – 18:00, meet by registration at 17:30**

The tennis competition will take place indoors at the Manchester Regional Tennis Centre, one of the great sporting legacies of the 2002 Commonwealth Games, located in the heart of the Sportcity complex. Participants should bring their own racquets and proper tennis shoes are required.

# COMMITTEE MEETINGS

## MON 5TH JULY:

| TIME          | MEETING  | ROOM       |
|---------------|--|------------|
| 16:00 – 18:00 | British Association of Dermatologists Officers | Exchange 4 |
| 18:30 – 19:30 | National Speciality Trainee Committee          | Exchange 2 |

## TUES 6TH JULY:

| TIME          | MEETING   | ROOM            |
|---------------|---|-----------------|
| 08:00 – 09:00 | British Society for Dermatopathology Exec Committee   | Exchange 2      |
| 08:00 – 09:00 | British Society for Paediatric Dermatology Training Committee   | Exchange 6      |
| 08:30 – 09:00 | The British Society of Cutaneous Allergy (BSCA) AGM (formally the British Contact Dermatitis Society) | Charter 3, 4, 5 |
| 10:00 – 12:00 | British Teledermatology Society   | Exchange 3      |
| 11:30 – 13:00 | British Skin Foundation Trustees  | Exchange 1      |
| 13:00 – 14:00 | Historical Collection Sub-Committee   | Exchange 4 / 5  |
| 13:00 – 15:00 | Community Dermatology Editorial Board   | Exchange 7      |
| 14:30 – 15:00 | British Society for Dermatopathology AGM  | Charter 3, 4, 5 |
| 14:30 – 16:30 | Clinical Services Committee   | Central Room 6  |
| 16:00 – 17:00 | Therapy & Guidelines  | Central Room 7  |
| 16:30 – 18:30 | BADBRL Management Committee   | Central Room 5  |
| 17:00 – 18:00 | British Society for Paediatric Dermatology Committee  | Exchange 2      |
| 17:00 – 18:00 | Audit & Clinical Standards  | Central Room 7  |
| 17:30 – 18:30 | Dermatology Teachers  | Central Room 6  |
| 17:30 – 18:30 | BAD Session Judging Committee   | Central Room 8  |

## WED 7TH JULY:

| TIME          | MEETING  | ROOM                 |
|---------------|--|----------------------|
| 11:00 – 13:00 | British Association of Dermatologists' AGM (Members Only)  | Exchange Auditorium  |
| 13:00 – 14:00 | British Association of Dermatologists Officers             | Exchange 4           |
| 13:00 – 14:30 | British Society for Dermatological Surgery Committee       | Exchange 6           |
| 13:00 – 14:30 | British Photodermatology Group Committee                   | Central Room 8       |
| 13:00 – 14:30 | British Cosmetic Dermatology Group AGM                     | Exchange 7           |
| 14:00 – 15:00 | British Association of Dermatologists' Executive Committee | Exchange 2 / 3       |
| 14:00 – 16:00 | British Journal of Dermatology                             | Exchange 5           |
| 14:00 – 16:00 | Health Informatics Sub-committee                           | Exchange 4           |
| 17:00 – 19:30 | Senior Skin Group  | Exchange 4           |
| 17:30 – 18:00 | UK Professors Group  | Exchange 6           |
| 17:30 – 18:00 | British Photodermatology Group AGM                         | Central Room 5, 6, 7 |
| 17:30 – 19:00 | BAD Session Judging Committee                              | Central Room 8       |
| 18:00 – 18:30 | British Society for Dermatological Surgery AGM             | Exchange Hall        |
| 18:15 – 19:15 | e-Learning Reception                                       | Exchange 3           |

## THURS 8TH JULY:

| TIME          | MEETING   | ROOM           |
|---------------|---|----------------|
| 08:30 – 09:30 | Exhibitors' Meeting                                     | Exchange 4     |
| 08:30 – 09:30 | UK DCTN Trial Prioritisation Panel                      | Exchange 6     |
| 08:30 – 10:30 | British Skin Foundation Grants Advisory                 | Exchange 7     |
| 10:30 – 12:00 | International Investigative Dermatology 2013 Committee  | Exchange 5     |
| 13:00 – 14:00 | Clinical and Experimental Dermatology Editorial Meeting | Exchange 1     |
| 13:00 – 14:30 | UKDCTN AGM/Steering Group                               | Exchange 7     |
| 13:00 – 17:00 | BAD Session Judging Committee                           | Central Room 8 |
| 15:15 – 17:15 | Biologics Steering Group                                | Central Room 5 |

# PROGRAMME INDEX

|  | <b>PAGE NUMBER</b> |
|--|--------------------|
| <b>MONDAY</b>                                |                    |
| Overview                                     | 17                 |
| <i>DermSchool</i>                            | 18                 |
| Trainee pre-conference session               | 19                 |
| SAS Session                                  | 20                 |
| <b>TUESDAY</b>                               |                    |
| Overview                                     | 21                 |
| Clinico-pathological cases – Joint BAD / BSD | 22 – 23            |
| Plenary                                      | 23 – 24            |
| British Society of Cutaneous Allergy         | 25 –26             |
| British Society for Paediatric Dermatology   | 27 – 28            |
| Historical                                   | 29                 |
| British Society for Dermatopathology         | 28 – 29            |
| <b>WEDNESDAY</b>                             |                    |
| Overview                                     | 33                 |
| Plenary                                      | 34                 |
| Medical Dermatology Plenary Session          | 35                 |
| BAD and BDNG Joint Meeting                   | 36                 |
| British Society for Dermatological Surgery   | 37 – 39            |
| British Photodermatology Group               | 40 – 41            |
| <b>THURSDAY</b>                              |                    |
| Overview                                     | 43                 |
| Professor’s & Registrars’ Forum              | 44 – 45            |
| CPD Session                                  | 45 – 46            |
| <b>Additional meetings</b>                   | <b>48</b>          |
| <b>Bristol Cup posters</b>                   | <b>49 – 55</b>     |
| <b>Satellite Symposia</b>                    | <b>56 – 58</b>     |



# MONDAY 5TH JULY – OVERVIEW

| Monday 5th July     | 08:00 - 08:15 | 08:30 - 08:45           | 09:00 - 09:15        | 09:30 - 09:45 | 10:00 - 10:15 | 10:30 - 10:45     | 11:00 - 11:15    | 11:30 - 11:45      | 12:00 - 12:15        | 12:30 - 12:45 | 13:00 - 13:15 | 13:30 - 13:45 | 14:00 - 14:15 | 14:30 - 14:45 | 15:00 - 15:15 | 15:30 - 15:45 | 16:00 - 16:15 | 16:30 - 16:45 | 17:00 - 17:15 | 17:30 - 17:45 | 18:00 - 18:15 | 18:30 - 18:45 |  |
|---------------------|---------------|-------------------------|----------------------|---------------|---------------|-------------------|------------------|--------------------|----------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|--|
| Exchange Auditorium |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Central Foyer       |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Central Hall 2      |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Exchange Hall       |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Charter 3           |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Charter 4           |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Charter 5           |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Exchange 1          |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Exchange 2          |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Exchange 3          |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Exchange 4          |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Exchange 5          |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Exchange 6          |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Exchange 7          |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Central Room 3      |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| Central Room 4      |               |                         |                      |               |               |                   |                  |                    |                      |               |               |               |               |               |               |               |               |               |               |               |               |               |  |
| KEY                 | BAD Sessions  | Special Interest Groups | Exhibition / Posters | BAD Committee | Focus Session | Additional Groups | Non-BAD Meetings | Satellite Symposia | Delegate Information | BDNG Session  |               |               |               |               |               |               |               |               |               |               |               |               |  |

# MONDAY 5TH JULY – OVERVIEW

# MONDAY 5TH JULY – DETAILED PROGRAMME

| TIME                 | CODE   | PROGRAMME  | VENUE  |
|----------------------|--------|--|--|
| 08:30 – 18:00        |        | Registration desk open   | Central Foyer  |
| <b>09:25 - 15:30</b> |        | <b>DERMSCHOOL PRE-CONFERENCE SESSION</b>   | <b>CHARTER 3</b>   |
| 09:00                |        | <b>Registration and Coffee</b>   |  |
| 09:25                |        | <b>Introduction</b><br>Dr Jane Sterling  |  |
|                      | CHAIRS | Dr Mini Singh and Dr Laura Proudfoot   |  |
| 09:30                | DE01   | <b>Common Skin Diseases (including recent advances treatment)</b><br><ul style="list-style-type: none"> <li>• <b>Eczema &amp; Acne</b>                      Dr Stuart Cohen</li> <li>• <b>Psoriasis</b>                                 Dr Richard Warren</li> <li>• <b>Skin infections</b>                         Dr Mini Singh</li> </ul> |  |
| 10:30                | DE02   | <b>Skin in Systemic disease</b> Dr Sandra Winhoven   |  |
| 11:00                |        | <b>Coffee</b><br><b>Posters</b>  | Exchange 4 / 5<br>Exchange 6 / 7   |
| 11:30                | DE03   | <b>Research in Dermatology</b><br>Professor Christopher Griffiths  |  |
| 12:00                | DE04   | <b>Career paths in Dermatology</b><br><ul style="list-style-type: none"> <li>• <b>A Day in the Life</b>                      Dr Venura Samarasinghe</li> <li>• <b>Career Planning</b>                         Dr Tamara Griffiths</li> </ul>   |  |
| 12:30                |        | ½ hour rotations<br>in assigned groups   | <ul style="list-style-type: none"> <li><b>Lunch</b>                                      Exchange 4 / 5</li> <li><b>Career Surgery</b>                         Charter 3</li> <li><b>Cryotherapy Workshop</b>             Charter 4 / 5</li> </ul> |
|                      | CHAIR  | Dr Jane Sterling   |  |
| 14:00                | DE05   | <b>Skin Cancer &amp; Surgery</b><br>Dr Ashley Cooper   |  |
| 14:30                | DE06   | <b>Dermatology for Exams</b><br>Dr Sue Burge   |  |
| 15:00                |        | Poster Prize   |  |
| 15:05                |        | Tea  | Exchange Hall  |
|                      |        | DERMSCHOOL DELEGATES JOIN TRAINEE SESSION  |  |

**NOTE:** Posters by DermSchool delegates to be on display in the Exchange 6 / 7 room (to include posters by elective prize winners)

# MONDAY 5TH JULY – TRAINEE PROGRAMME

| 12:55 – 18:20 | TRAINEE PRE-CONFERENCE SESSION  | EXCHANGE HALL |
|---------------|---|---------------|
| 12:15 – 12:55 | Welcome Lunch   | Exchange Hall |
| 12:55         | Introduction – Dr Laura Proudfoot and Dr David de Berker              |               |
| 13:00         | <b>TPC01 Pregnancy dermatosis</b><br>Dr Karen Gibbon                  |               |
| 13:45         | <b>TPC02 Haemangiomas</b><br>Dr Cameron Kennedy                       |               |
| 14:30         | <b>TPC03 SCE Update</b><br>Dr Richard Groves                          |               |
| 15:00         | <b>DermSocs – the BAD Student Group</b><br>Dr Ketaki Bhate            |               |
| 15:05         | <b>Tea / Coffee</b><br>Trainees then joined by DermSchool delegates   |               |
| 15:30         | <b>TPC04 Derm Clinics</b><br>Dr David de Berker & Dr Jonathan Bowling |               |
| 16:15         | <b>TPC05 Dermoscopy</b><br>Dr Jonathan Bowling                        |               |
| 17:00         | <b>TPC06 Genodermatoses</b><br>Dr Jemma Mellerio                      |               |
| 17:45         | <b>TPC07 Forensic Dermatology</b><br>Dr Jason Payne-James             |               |
| 18:15         | <b>Dowling Club</b><br>Dr Mike Beck & Dr Anja Weidmann                |               |
| 18:20         | Close   |               |
| 19:00 – 23:00 | Trainee & <i>DermSchool</i> evening event                             | Bar 38        |

# MONDAY 5TH JULY – SAS PROGRAMME

13:55 – 17:35 STAFF AND ASSOCIATE SPECIALISTS SESSION

EXCHANGE 1

## A tour of the Special Interest Groups

|               |   |            |
|---------------|---|------------|
| 12:15 – 13:00 | Registration  |            |
| 12:15 – 13:00 | Welcome Lunch   | Exchange 2 |
| 13:00         | <b>Welcome and Introduction – Dr Glenda Hill</b>  |            |
| 13:05         | <b>Historical Archive</b><br><b>Silk Route</b><br>Dr Paul Yesudian  |            |
| 13:45         | <b>Paediatric Dermatology</b><br><b>Neonatal Dermatology</b><br>Dr Lindsay Shaw                                 |            |
| 14:25         | <b>Contact Dermatitis</b><br><b>Immediate Contact Reactions &amp; Supplementary testing</b><br>Dr Sarah Wakelin |            |
| 15:05         | Tea / Coffee  | Exchange 2 |
| 15:35         | <b>Dermatopathology</b><br><b>Amyloidosis-Clinical &amp; pathological variants</b><br>Dr Ian Coulson            |            |
| 16:15         | <b>Dermatological Surgery</b><br><b>Update on Lasers</b><br>Dr Sean Lanigan                                     |            |
| 16:55         | <b>Photodermatology</b><br><b>All you need to know about PLE</b><br>Dr Jane McGregor                            |            |
| 17:35         | <b>Closing remarks</b>  |            |
| 19:00 – 22:00 | SAS evening event   | Barbirolli |

# TUESDAY 6TH JULY – OVERVIEW



| Tuesday 6th July    | 08:00 - 09:00           | 09:00 - 10:00                              | 10:00 - 11:00        | 11:00 - 12:00                              | 12:00 - 13:00 | 13:00 - 14:00              | 14:00 - 15:00    | 15:00 - 16:00                      | 16:00 - 17:00        | 17:00 - 18:00                           | 18:00 - 19:00     |
|---------------------|-------------------------|--|----------------------|--|---------------|----------------------------|------------------|------------------------------------|----------------------|---|-------------------|
| Exchange Auditorium |                         |  |                      |  |               |                            |                  |                                    |                      |   |                   |
| Central Foyer       | Registration Open       |  |                      |  |               |                            |                  |                                    |                      |   |                   |
| Central Hall 2      | Exhibition              |  |                      |  |               |                            |                  |                                    |                      |   |                   |
| Exchange Hall       |                         | British Society for Paediatric Dermatology |                      | British Society for Paediatric Dermatology |               | Satellite Symposium Pfizer |                  | Taking Dermatology Nursing Forward |                      | BDNG Taking Dermatology Nursing Forward | Welcome Reception |
| Charter 3           |                         | British Society of Cutaneous Allergy       |                      | British Society of Cutaneous Allergy       |               | Satellite Symposium Abbott |                  | British Society Dermatopathology   |                      | British Society Dermatopathology        |                   |
| Charter 4           |                         | BSCA AGM                                   |                      | BSCA Guest Lecture                         |               |                            |                  | BSD AGM                            |                      |   |                   |
| Charter 5           |                         | BSD & Clinicopath Cases                    |                      | BSD & Clinicopath Cases                    |               |                            |                  | Scientific Session                 |                      | Scientific Sessions                     |                   |
| Exchange 1          |                         | BSD Exec Briefing                          |                      | BSF Trustees                               |               |                            |                  | Guest Lecture                      |                      | Guest Lecture                           |                   |
| Exchange 2          | BSD Executive           |  |                      | Azathioprine guidelines (final) meeting    |               |                            |                  |                                    |                      |   |                   |
| Exchange 3          |                         | British Teledermatology Society            |                      |  |               |                            |                  |                                    |                      |   |                   |
| Exchange 4          |                         |  |                      | Historical Symposium                       |               |                            |                  |                                    |                      |   |                   |
| Exchange 5          |                         |  |                      | Historical Symposium                       |               | Historical Committee       |                  |                                    |                      |   |                   |
| Exchange 6          | BSPD Training committee |  |                      |  |               |                            |                  |                                    |                      |   |                   |
| Exchange 7          |                         |  |                      | Historical Symposium Lunch                 |               |                            |                  |                                    |                      |   |                   |
| Central Room 3      | Cloakroom               |  |                      |  |               |                            |                  |                                    |                      |   |                   |
| Central Room 4      | Speaker Preview         |  |                      |  |               |                            |                  |                                    |                      |   |                   |
| Central Room 5      |                         |  |                      | BDNG AGM                                   |               |                            |                  |                                    |                      |   |                   |
| Central Room 6      |                         |  |                      |  |               |                            |                  |                                    |                      |   |                   |
| Central Room 7      |                         |  |                      |  |               |                            |                  |                                    |                      |   |                   |
| Central Room 8      |                         |  |                      |  |               |                            |                  |                                    |                      |   |                   |
| KEY                 | BAD Sessions            | Special Interest Groups                    | Exhibition / Posters | BAD Committee                              | Focus Session | Additional Groups          | Non-BAD Meetings | Satellite Symposia                 | Delegate Information | BDNG Session                            |                   |

# TUESDAY 6TH JULY – OVERVIEW

# TUESDAY 6TH JULY – DETAILED PROGRAMME

| TIME          | CODE         | PROGRAMME   | VENUE                  |
|---------------|--------------|---|------------------------|
| 07:30 – 18:00 |              | Registration desk open  | Central Foyer          |
| 09:00 – 12:45 |              | <b>BRITISH SOCIETY OF CUTANEOUS ALLERGY</b><br>(PAGE 25 – 26)   | <b>CHARTER 3, 4, 5</b> |
| 09:00 – 12:45 |              | <b>BRITISH SOCIETY FOR PAEDIATRIC DERMATOLOGY</b><br>(PAGE 27 – 28)   | <b>EXCHANGE HALL</b>   |
| 09:30 – 10:28 |              | <b>CLINICOPATHOLOGICAL CASES</b><br>Joint meeting with the British Society of Dermatopathology  | Exchange Auditorium    |
|               | CHAIRS       | Dr Maureen Walsh & Dr Robert Lister   |                        |
| 09:30         | <b>CPC-1</b> | <b>Multifocal presentation of a rare condition</b><br><u>B. Arun</u> , L. Jamieson and E. Stewart   |                        |
| 09:37         | <b>CPC-2</b> | <b>Pemphigoid gestationis requiring oophorectomy</b><br><u>A. Sinha</u> , S. Darne, P. Barrett, C. Steele and C. Blasdale   |                        |
| 09:44         | <b>CPC-3</b> | <b>Blaschkoid Darier disease in association with bullous pemphigoid</b><br><u>A. Sherley-Dale</u> , R. Carr and B. Dharma   |                        |
| 09:51         | <b>CPC-4</b> | <b>Familial lichen amyloidosis with partial response to narrowband ultraviolet B radiation in the presence of an OSMR gene mutation and negative RET proto-oncogene mutation</b><br><u>A.E. Macbeth</u> , A. Tanaka, N. Nagy, A. Ali, N.J. Levell, J.A. McGrath and G.W.M. Millington |                        |
| 09:58         | <b>CPC-5</b> | <b>An unusual presentation of systemic AL amyloidosis: bulla and milia formation</b><br><u>A. Pink</u> , C. Stefanato and S.M. Breathnach   |                        |
| 10:05         | <b>CPC-6</b> | <b>Clinical coexpression of widespread vitiligo, with sarcoidosis and psoriasiform change</b><br><u>N.C. Chetty</u> , L. Igali, J. Garioch, S. Shah and G.W.M. Millington   |                        |
| 10:12         | <b>CPC-7</b> | <b>Tyrosine kinase inhibitor induced palmoplantar annular erosions: a class effect</b><br><u>A. Fityan</u> , C. Morgan, C.J.M. Stephens and A. Belgi  |                        |
| 10:19         | <b>CPC-8</b> | <b>Cutaneous mucormycosis in a patient with acute myeloid leukaemia</b><br><u>T.T. Lew</u> , T. Lewis, P. Dunn, N. Pemberton and C. Bertram   |                        |
| 10:28 – 11:14 |              | Coffee & Exhibition   | Central 2              |
| 11:00 – 12:00 |              | <b>HISTORICAL COLLECTION SYMPOSIUM (PAGE 29)</b>  | <b>EXCHANGE 4, 5</b>   |
| 11:14 – 12:40 |              | <b>CLINICOPATHOLOGICAL CASES CONTINUED...</b>   | Exchange Auditorium    |
|               | CHAIRS       | Dr Saleem Taibjee & Dr Chris Dobson   |                        |
| 11:14         | <b>CPC-9</b> | <b>A rare case of vulval pustulation in rosacea fulminans</b><br><u>J. Hafiji</u> , C. Sonnex, E. Rytina and J.C. Sterling  |                        |

|                      |               |   |                      |
|----------------------|---------------|---|----------------------|
| 11:21                | <b>CPC-13</b> | <b>Two unusual cases of antiphospholipid syndrome mimicking necrotizing fasciitis and periorbital cellulitis</b><br><u>M.G. Khorasgani</u> , P. Mensah, R. Simpson, A. Fletcher, G. Saldanha, G.A. Johnston and K.E. Harman   |                      |
| 11:28                | <b>CPC-11</b> | <b>Hepatitis B associated type I monoclonal cryoglobulinaemia, presenting with cutaneous vasculitis, treated with rituximab</b><br><u>K. Lee</u> , A. Heaton, A-M. Skellett, T. Barker, D. Scott and G.W.M. Millington  |                      |
| 11:35                | <b>CPC-12</b> | <b>Bullous pyoderma gangrenosum and arthritis: clonal T-cell receptor gene rearrangements in skin and synovium</b><br><u>C. Hackett</u> , C. Cunningham, M.F. Doran, G. Cunane and L. Barnes  |                      |
| 11:42                | <b>CPC-10</b> | <b>Azathioprine hypersensitivity presenting as erythema nodosum-like lesions in a patient with ulcerative colitis</b><br><u>L. Paul</u> and V. Goulden  |                      |
| 11:49                | <b>CPC-14</b> | <b>Perniotic lesions as an indicator of coexisting or potential systemic disease</b><br><u>A. Fogo</u> and J.D. Creamer   |                      |
| 11:56                | <b>CPC-15</b> | <b>'Hands only': two distinctive cases of neutrophilic dermatosis of the hands</b><br><u>M.I. Darling</u> , S.J. Fraser, M.E. Mathers and G.M. Kavanagh   |                      |
| 12:03                | <b>CPC-16</b> | <b>Linear cutaneous lupus erythematosus</b><br><u>N. Aldoori</u> and J. Kellett   |                      |
| 12:10                |               | Joint BAD/BSA Neil Smith Lecture<br><b>Interface dermatitis and connective tissue disease</b><br>Dr Martin Mihm (Boston)  |                      |
| 12:45 – 14:30        |               | Lunch & Exhibition  | Central 2            |
| <b>13:15 – 14:15</b> |               | <b>PFIZER SATELLITE SYMPOSIUM (PAGE 56)</b>   | <b>EXCHANGE HALL</b> |
| <b>13:15 – 14:15</b> |               | <b>ABBOTT SATELLITE SYMPOSIUM (PAGE 56)</b>   | <b>CHARTER 3,4,5</b> |
| <b>14:30 – 18:00</b> |               | <b>BRITISH SOCIETY FOR DERMATOPATHOLOGY (PAGE 30 – 31)</b>  | <b>EXCHANGE HALL</b> |
| 14:30 – 18:00        |               | <b>SCIENTIFIC SESSION</b> - SUBMITTED PAPERS  | Exchange Auditorium  |
|                      | CHAIRS        | Dr Mark Goodfield & Dr Stephen Jones  |                      |
| 14:30                |               | Official Opening & Welcome - Mark Goodfield   |                      |
| 14:45                | <b>O-1</b>    | <b>Skin conditions are the commonest new reason people present to general practitioners in England and Wales: implications for education and training</b><br><u>J. Schofield</u> , D. Fleming, D. Grindlay and H. Williams  |                      |
| 15:00                | <b>O-2</b>    | <b>The role of the dermatologist in reducing the length of inpatient stays: an audit demonstrating dispensing of topical agents by the dermatology team results in expedient treatment</b><br><u>A.C. Sherley-Dale</u> , C. Jones, W. Bakkour, J. Carter and B.C. Gee |                      |
| 15:15                | <b>O-3</b>    | <b>The role of invariant natural killer T cells in psoriasis</b><br><u>A.-M. Tobin</u> , A. Hogan, L. Lynch, S. Rogers, P. Collins, D. O'Shea and B. Kirby  |                      |

|               |             |  |                            |
|---------------|-------------|--|----------------------------|
| 15:30         | <b>GL01</b> | <p>Guest Lecture 1 –introduced by Dr Stephen Jones</p> <p><b>From genes to function and therapy in Psoriasis</b><br/>Professor Frank Nestle (London)</p>    | Exchange Auditorium        |
| 16:00 – 16:30 |             | Tea and Exhibition   | Central 2, Exhibition Hall |
| 16:30         | <b>O-4</b>  | <p><b>Location and regulation of sunbed outlets</b><br/><u>N. Bowtell</u>, V. Poirier, S. Harris, S. Smith, S. McPhail and J. Verne</p>  |                            |
| 16:45         | <b>O-5</b>  | <p><b>Tele dermatology triage for suspected skin cancers: an audit of service quality and effectiveness in a Northern Irish dermatology centre</b><br/>A. O’Hagan, R. Black, <u>E. McCallion</u>, C. Ross, L. Godfrey, J. Collins, A. Herron and D.J. Eedy</p>   |                            |
| 17:00         | <b>O-6</b>  | <p><b>Demonstration of novel innate immune cells in psoriasis skin</b><br/><u>R.K.H. Mak</u>, C. Hundhausen, E. Botti, K. Grys and F.O. Nestle</p>   |                            |
| 17:15         | <b>O-7</b>  | <p><b>Revertant mosaicism in Kindler syndrome resulting from FERMT1 transcriptional gene correction</b><br/><u>J. Lai-Cheong</u>, T. Techanukul, M. Parsons, C. Moss and J.A. McGrath</p>  |                            |
| 17:30 – 18:00 | <b>GL02</b> | <p>Guest Lecture 2 –introduced by Prof Alex Anstey</p> <p><b>Research and all that goes with it in the UK</b><br/>Sir Leszek Borysiewicz (London)</p>  <p>Sir Leszek will examine the current and future position of biomedical research in the United Kingdom. Reflecting on the enviable global position the UK currently holds in this field, and looking towards how this can be sustained in the future. Addressing key issues including; the sustainability of the current model of research and funding in the UK, the necessity of academic-industry interface and how the UK can continue to be a major global player despite competition.</p> | Exchange Auditorium        |
| 18:00 – 19:30 |             | Welcome Reception  | Central 2, Exhibition Hall |
| 19:30 – 23:00 |             | BSDS Annual Dinner   | Manchester Art Gallery     |



# TUESDAY 6TH JULY – THE BRITISH SOCIETY OF CUTANEOUS ALLERGY

| TIME | PROGRAMME | VENUE |
|------|-----------|-------|
|------|-----------|-------|

|               |  |               |
|---------------|--|---------------|
| 09:00 – 12:30 | THE BRITISH SOCIETY OF CUTANEOUS ALLERGY | CHARTER 3,4,5 |
|---------------|--|---------------|

- |        |   |              |
|--------|---|--------------|
| CHAIRS | Dr Mark Wilkinson & Dr John McFadden  |              |
| 09:00  | Prosser – White Oration<br><b>Hand eczema – diagnosis, treatment and prevention</b><br>Dr Tove Agner (Copenhagen, Denmark)  |              |
| 09:45  | <b>CD01 – Nine years’ experience of patch testing to investigate footwear allergic contact dermatitis: can the distribution of rash help predict the cause of the dermatitis or the allergens involved?</b><br><u>R.Y.P. Hunasehally</u> , T.M. Hughes and N.M. Stone |              |
| 09:55  | <b>CD02 – Allergic contact dermatitis to methylene-bis-benzotriazolyl tetramethylbutyl phenol</b><br><u>M. O’Connell</u> and M. Wilkinson   |              |
| 10:02  | <b>CD03 – A case report of cross-sensitization between latex, potato and yellow bell pepper: the latex-fruit syndrome and review of the literature</b><br><u>V. Samarasinghe</u> , G. Street, M.H. Beck, J.D.L. Williams  |              |
| 10:12  | <b>CD04 – Allergic contact dermatitis to methyl hydroxystearate in a rubber respirator</b><br><u>E. Benton</u> , I.R. White, J.M.L. White and J. McFadden   |              |
| 10:19  | <b>CD05 – A retrospective review of patch test results in individuals working in the printing industry</b><br><u>S. Ogden</u> , J. Newsham, M.H. Beck and J. Williams   |              |
| 10:29  | <b>CD06 – The importance of patch testing, even in ‘classical scenarios’</b><br><u>F. Al-Niaimi</u> , J. Williams and R. Nalluri  |              |
| 10:36  | COFFEE  | Central Hall |
| CHAIRS | Dr David Orton & Dr Jason Williams  |              |
| 11:05  | <b>CD07 – Patch testing for perineal dermatitis: 13 years’ experience</b><br><u>M.A. McAleer</u> and J. Bourke  |              |
| 11:15  | <b>CD08 – A rare case of acquired leucoderma following patch testing to acrylate series</b><br><u>C. Kwok</u> , M. Wilkinson and S. Sommer  |              |
| 11:22  | <b>CD09 – The prevalence of allergic contact dermatitis remains high in patients with leg ulcers despite the widespread introduction of ‘hypoallergenic’ dressings</b><br><u>G. Kaushal</u> and S. Cooper   |              |
| 11:32  | <b>CD13 – Severe allergic contact dermatitis from shoes due to dimethyl fumarate</b><br><u>M. Alrawi</u> and J. Sansom  |              |

- 11.39 **CD11 – Erythematous reactions on removing Scanpor® tape in patch testing are not necessarily caused by dermatographism**  
M. Simms, I.R. White and J.M.L. White
- 11.46 **CD12 – Investigating contact allergy to CS gas**  
K. Bhargava, P. Banerjee and I.R. White
- 11.53 **CD10 – An outbreak of occupational allergic contact dermatitis to 2-N-octyl-4-isothiazolin-3-one among workers in an adhesive factory**  
M.G. Khorasgani and G. Johnston
- 12:03 **CD14 – The role of patch testing in chronic urticaria**  
A. Kai, C. Grattan, I.R. White and J.M.L. White
- 12:10 **CD15 – The role of patch testing in the management of oral lichenoid reactions of uncertain aetiology**  
M. Lynch, N. O'Rourke, A. Ryan, S. Flint, C. Healy, S.C.F. Rogers and P. Collins
- 12:17 **CD16 – Allergic contact dermatitis to methylchloroisothiazolinone and ethylenediamine. Which paint is safe?**  
D. Shah and M.M.U. Chowdhury
- 12:24 **CD17 – Photoallergic contact dermatitis to isoamyl methoxycinnamate in an organic sunscreen**  
M. Ghazavi Khorasgania and G. Johnston
- 12:34 **CD18 – Retrospective review of 282 patients who were patch tested for vulval symptoms**  
F. Al-Niaimi, J. Williams and C. Pavey
- POSTERS **CD19 – Occupational allergic contact dermatitis to artificial nails in a professional male guitarist**  
R. Nalluri, F. Al-Niaimi and J. Williams
- CD20 – Allergic contact dermatitis to copolymers**  
A. Kai, M. Khorshid and J. McFadden
- CD21 – Acrylates tooth and nail: coexistent allergic contact dermatitis to acrylates present in desensitizing dental swabs and artificial fingernails**  
J.M.R. Goulding and T.M. Finch
- CD22 – Sleepover dermatitis: allergic contact dermatitis to 2-mercaptobenzothiazole in an air mattress**  
C. Allen, S.M. Burge and S. Cooper
- CD23 – Contact allergy to chromate in an infant**  
R. Regester and M. Wilkinson
- CD24 – Nickel allergy and allergic contact dermatitis to embroidered Indian clothing**  
A. Woods and L. Ostlere

# TUESDAY 6TH JULY

## – BRITISH SOCIETY FOR PAEDIATRIC DERMATOLOGY

| TIME          | PROGRAMME   | VENUE               |
|---------------|---|---------------------|
| 09:00 – 12:45 | BRITISH SOCIETY FOR PAEDIATRIC DERMATOLOGY  | EXCHANGE HALL       |
| CHAIR         | Dr Pamela McHenry   |                     |
| 09:00         | <b>PA01 – Oral corticosteroids are not required for the successful management of kerions</b><br><u>L.E. Proudfoot</u> , M. Cunningham, E.M. Higgins and R. Morris-Jones               |                     |
| 09:10         | <b>PA02 – To re-scrape, or not to re-scrape: that is the question</b><br><u>L. Duckworth</u> , B. Kodz-Gibb and A. Abdullah   |                     |
| 09:20         | <b>PA03 – The new face of congenital melanocytic naevi</b><br><u>V. Kinsler</u> , A. Shaw and R. Hennekam   |                     |
| 09:30         | <b>PA04 – Novel ABCA12 mutations in harlequin ichthyosis and a review of clinical outcomes</b><br><u>S. Rajpopat</u> , E. O’Toole and D. Kellsell                                     |                     |
| 09:40         | <b>PA05 – Hyper-IgE syndrome: how easy is it to diagnose?</b><br><u>J. Kluk</u> , H. Goodyear and A. Loffeld  |                     |
| 09:50         | <b>Guest Lecture</b><br><b>What’s new in vasculitis of the young</b><br>Dr Paul Brogan (London)   |                     |
| 10:30         | <b>Tea</b>  | <b>Central Hall</b> |
| CHAIR         | Dr Olivia Schofield   |                     |
| 11:05         | <b>PA06 – The use of etanercept in children and adolescents with moderate-to-severe plaque psoriasis: a report of three successful cases</b><br><u>S. Cheng</u> and R. Murphy         |                     |
| 11:15         | <b>PA07 – A survey examining the use of phototherapy in a paediatric population</b><br><u>M. Walsh</u> , S. Dolman, G. Sharpe, T. Clayton and R.A.G. Parslew                          |                     |
| 11:25         | <b>PA08 – Severity stratification of Children’s Dermatology Life Quality Index (CDLQI) scores</b><br><u>A. Waters</u> , D. Sandhu, P. Beattie, F. Ezughah and S. Lewis-Jones          |                     |
| 11:35         | <b>PA09 – The role of the school nurse in managing atopic eczema</b><br><u>A. Aslam</u>   |                     |
| 11:45         | <b>PA10 – Shin pad eczema: an under-recognized phenomenon?</b><br><u>C. Roberts</u> , S. Lawton, J.S.C. English and J.C. Ravenscroft  |                     |
| 11:55         | <b>PA16 – Discrete papular mucinosis, a rare subtype of lichen myxoedematosus occurring in a teenage girl</b><br><u>R.Y.P. Hunasehally</u> , R.G. Goodwin, L. Intzedy and I. Thompson |                     |

- 12:01 **PA12 – Anti-IgE in the management of severe paediatric eczema unresponsive to conventional systemic therapy**  
S.M.H. Chan, P. Kane, A.-M. Powell, D.J. Atherton and G. Lack
- 12:07 **PA13 – Transient aquagenic palmar hyperwrinkling: three paediatric cases**  
A.V. Sears, V.R. Doherty, O.M.V. Schofield and M.J. Tidman
- 12:13 **PA14 – Novel heterozygous frameshift mutations of the desmoplakin gene presenting with hair shaft abnormalities and culminating in lethal cardiomyopathy**  
P.D. Yesudian, A.M. Christiano, E.J. Ladusans, S. Spinty, J. Gibbs, A. Fryer and S.S. Mendelsohn
- 12:19 **PA15 – An unusual cutaneous manifestation of immunodeficiency: disseminated BCGosis and axillary abscess associated with interleukin-12/interferon- pathway deficiency**  
A. Mahto, G. Tudor-Williams and C. Hardman
- 12:25 **PA11 – Sole dermatitis in children: patch testing revisited**  
M.J. Darling, H.M. Horn, S.K.A. McCormack and O.M.V. Schofield
- Close
- Posters**
- PA17 – A case series showing the range of cutaneous presentations of juvenile systemic lupus erythematosus**  
A. Patel and R. Murphy
- PA18 – Propranolol for ulcerated haemangioma in a preterm baby: our experience**  
R. Gulati and C. Jury
- PA19 – Bleach baths using Milton® sterilizing fluid for recurrent infected atopic dermatitis**  
C. Vlachou, K. Batta, K. Pett and G. Nicholls
- PA20 – Acquired reactive perforating collagenosis in Down syndrome**  
J. Hafiji, E. Hook and N.P. Burrows
- PA21 – A rare presentation of a systemic disease rarely seen in childhood: sarcoidosis**  
A. Fogo and E.M. Higgins
- PA22 – Disseminated orf infection in a 13-year-old boy with atopic dermatitis**  
E. Higgins, M. Bennett, S. Curran, A. Murphy and T. Markham
- PA23 – Poikilodermatous truncal eruption in a 15-year-old boy: a unique clinical presentation of macular arteritis**  
C. Cunningham and B. O'Donnell
- PA24 – An audit of adherence to the National Institute for Health and Clinical Excellence (NICE) guidelines on the management of atopic eczema in children**  
C. Devereux and S. Hoey
- PA25 – Compositae allergy in two children with hand dermatitis**  
D. Coates, S. Cooper and S.M. Burge
- PA26 – The presence of IgE-mediated food allergy and poor weight gain in a series of children under 2 years of age with atopic eczema**  
A. Woods and R.A. Marsden

# TUESDAY JULY 6TH – DETAILED PROGRAMME

| TIME          | CODE       | PROGRAMME  | VENUE                     |
|---------------|------------|--|---------------------------|
| 11:00 – 12:00 |            | <b>HISTORICAL SYMPOSIUM</b>  | <b>EXCHANGE 4 &amp; 5</b> |
|               | CHAIR      | Dr Nick Levell   |                           |
| 11:00         | <b>H01</b> | <b>Niels Ryberg Finsen: the only dermatologist to be awarded the Nobel Prize for medicine</b><br><u>L. Paul</u>                  |                           |
| 11:15         | <b>H02</b> | <b>A tribute to Robert Willan in Bloomsbury Square</b><br><u>S. Walker</u>   |                           |
| 11:30         |            | Guest Lecture<br><b>90 years on: Sir Archibald Gray, The Founder of the BAD 1920 – 2010</b><br>Dr Sid Orpin (Solihull)           |                           |
| 12:00 – 13:00 |            | Historical Symposium Lunch   | Exchange 6                |
| POSTERS       | <b>H03</b> | <b>Doctors of the Wild Wart</b><br>H. Thomas and <u>P.D. Yesudian</u>  |                           |
|               | <b>H04</b> | <b>The Weals of Time: a historical perspective of chronic urticaria</b><br><u>E. Borzova</u> , C. Grattan and N.J. Levell        |                           |
|               | <b>H05</b> | <b>Shedding some light on skin disease: three and a half centuries of skin surface microscopy</b><br><u>U. Eke</u> and S. Orpin  |                           |
|               | <b>H06</b> | <b>The bridge from west to east: Paulus Aegineta (AD 625–690)</b><br><u>M. Chriba</u> and N.J. Levell                            |                           |
|               | <b>H07</b> | <b>A. Bernard Ackerman (1936–2008): a Princeton tiger finally rests</b><br><u>A. Sherley-Dale</u>                                |                           |
|               | <b>H08</b> | <b>Healing votive offerings in dermatology</b><br><u>S. Tzortzis</u> and R. Arnott   |                           |
|               | <b>H09</b> | <b>The changing face of lupus: from wolf bites to stem cell transplantation</b><br><u>C. Kasparis</u> and J. Gach                |                           |
|               | <b>H10</b> | <b>Erythema elevatum diutinum: the lost art of clinical description</b><br><u>T. Maruthappu</u> and S. Tharakaram                |                           |
|               | <b>H11</b> | <b>Pellagra: the first published photosensitivity syndrome</b><br><u>P. Wan</u> and A.V. Anstey                                  |                           |
|               | <b>H12</b> | <b>German National Socialism: decline, desertion of dermatology</b><br><u>P.D. Yesudian</u> , P. Balasubramaniam and P. Yesudian |                           |
|               | <b>H13</b> | <b>Changing patterns of U.K. dermatology publications 1919–2009</b><br><u>G. Ali</u> , A. Shipman and N.J. Levell                |                           |

# TUESDAY 6TH JULY

## – BRITISH SOCIETY FOR DERMATOPATHOLOGY

| TIME                 | PROGRAMME  | VENUE                |
|----------------------|--|----------------------|
| 08:00 – 09:00        | Executive BSD Committee Meeting  | Exchange 2           |
| 09:30 – 12:30        | Clinicopathological Cases, Joint meeting with the British Association of Dermatologists  | Exchange Auditorium  |
| 12:30 – 13:00        | Joint BAD/BSD Neil Smith Lecture<br><b>Interface dermatitis and connective tissue disease</b><br>Dr Martin Mihm (Boston, USA)) | Exchange Auditorium  |
| 14.30 – 15.00        | BSD AGM  | Charter 3,4,5        |
| <b>15:00 – 18:00</b> | <b>BSD MAIN PROGRAMME</b>  | <b>CHARTER 3,4,5</b> |

Chair: Dr Maureen Walsh

15:00 **Review of vascular lesions with emphasis on childhood lesions**  
Dr Martin Mihm (Boston, USA)

15:45 **Introduction and comment on posters**

15:49 **DP01 – Multicentric epithelioid haemangioendothelioma of the penis**  
F. Al-Niaimi, S. Shaktawat, G. Hall, L. McWilliam, V. Sangar and I.H. Chaudhry

15:56 **DP02 – Painful mutilating ulceration of the dorsolateral foot in diplegics with acroangiokeratosis of Mali**  
J. Vyas, S. Howarth, D. Coleman, E. Calonje, N. Ivins, K.G. Harding and G.K. Patel

16:03 **DP03 – A congenital painful ulcerated vascular plaque: eccrine angiomatous hamartoma requiring deep surgical excision**  
S. Rai, V. Madan, P.J. August and L.A. Jamieson

16:10 – 16:40 Coffee Central Hall

Chair: Dr Saleem Taibjee

16:40 **DP04 – Diffuse dermal angiomatosis: a rare and distinctive ulcerative dermatosis of the breasts**  
S. Rai, Y. Mukasa, D. Fairhurst, W. Salman, W. Merchant and I.H. Coulson

16:47 **DP05 – Unravelling cylindromas: insights into appendageal tumour patterning from patients with truncating CYLD mutations**  
N. Rajan, K. Gillinder, C. Lord, J.A.A. Langtry, J. Burn, A. Ashworth, B. Chaudhury and M. Sieber-Blum

16:54 **DP06 – Follicular variant of squamous cell carcinoma: a series of 30 cases**  
J. Carter, T. Preece, S. Taibjee, S. Sanders and R. Carr

17:01 **DP07 – With a clinical suspicion of melanoma or atypical naevus, does the type of biopsy impact the efficient use of resources and ability of the pathologist to provide the pertinent information for appropriate management of the patient?**  
C. Sladden and R.I. Crawford

17:08 **DP08 – Dermoscopy of fading naevi**  
R. Vyas, A. Oakley and M. Rademaker

- 17:15 **DP09 – Histopathological review of 78 cases of cicatricial alopecia at one U.K. centre**  
S.A. Thiryayi, M.J. Harries, E. White, C.E.M. Griffiths, R. Paus and I.H. Chaudhry
- 17:22 **DP11 – Parastomal pyoderma gangrenosum successfully treated with adalimumab**  
A. Ryan, K. Sheahan and B. Kirby
- 17:29 **DP12 – A novel case of follicular mucinosis following autologous stem cell transplant for multiple myeloma**  
S. Cheng, I.H. Leach and W. Perkins
- 17:36 **DP13 – A review of 15 cases of cutaneous angioimmunoblastic T-cell lymphoma**  
E. Benton, B. Martin, K. Naresh and A. Robson
- 17:42 **DP14 - Invasive ductal carcinoma and ductal carcinoma in situ arising within a naevus sebaceus of Jadassohn: the use of immunohistochemical markers to recognize invasion**  
L. Smith and E. Husain
- 17:49 **DP15 – Three cases of CD20+ primary cutaneous T-cell lymphoma**  
B. Martin, C. Stefanato, S.J. Whittaker and A. Robson
- 17:56 **DP16 – Lichen scrofulosorum-like clinical presentation with unusual histology**  
M. Sivaramakrishnan, A. Mishra, A. Barbieri and P. Woo
- 18:03 Best presentation prize and close
- Posters **DP17 - A painful nail**  
R. Vyas, D. Lamont and A. Yung
- DP18 – Necrolytic migratory erythema in a patient with pseudoglucagonoma syndrome due to a pancreatic carcinoid tumour**  
E.A. Langan, L.A. Jamieson and H. Young
- DP19 – Subcutaneous presentation of primary cutaneous follicle centre cell lymphoma: a taxonomic dilemma?**  
E. Benton, A. Eichholz, S.J. Whittaker, S. Morris and A. Robson
- DP20 – Goltz syndrome: a mild case with delayed diagnosis**  
S.L. Chua, M. Khan, C. Moss and J.C. Ravenscroft
- DP21 – Epstein–Barr virus-positive methotrexate-associated lymphoma in a patient with rheumatoid arthritis**  
E. Craythorne, J. Scarisbrick and A. Robson
- DP22 – The t(14;18) translocation is rarely encountered in primary cutaneous follicle centre lymphoma**  
A. Abdul-Wahab, N. Agar, A. Robson, F. Child, J. Scarisbrick, M. Neat, T. Mitchell, S. Tang, S. Morris and S.J. Whittaker
- DP23 – Waldenström’s macroglobulinaemia with amyloid deposition presenting in the ears**  
R. Healy, M. Saha, A. Rohatiner and R. Cerio
- DP24 – Granulomatous T-cell lymphoma in association with yellow nail syndrome**  
N. Anjum and I.C. Pearson





# WEDNESDAY 7TH JULY – OVERVIEW

| Wednesday<br>7th July | 08:00 - 09:00             | 9:00 - 10:00              | 10:00 - 11:00             | 11:00 - 12:00             | 12:00 - 13:00             | 13:00 - 14:00             | 14:00 - 15:00             | 15:00 - 16:00             | 16:00 - 17:00             | 17:00 - 18:00             | 18:00 - 19:00             | 19:00 - 20:00             |
|-----------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Exchange Auditorium   | Submitted papers          | Submitted papers          | Submitted papers          | Submitted papers          | Submitted papers          | Submitted papers          | Submitted papers          | Submitted papers          | Submitted papers          | Submitted papers          | Submitted papers          | Submitted papers          |
| Central Foyer         | Guest Lecture             | Annual General Meeting    | Registration Open         | Registration Open         | Registration Open         | Registration Open         | Registration Open         | Registration Open         | Registration Open         | Registration Open         | Registration Open         | Registration Open         |
| Central Hall 2        | Exhibition                | Exhibition                | Exhibition                | Exhibition                | Exhibition                | Exhibition                | Exhibition                | Exhibition                | Exhibition                | Exhibition                | Exhibition                | Exhibition                |
| Exchange Hall         | BDNG - Policy to practice | BDNG - Policy to practice | BDNG - Policy to practice | BDNG - Policy to practice | BDNG - Policy to practice | BDNG - Policy to practice | BDNG - Policy to practice | BDNG - Policy to practice | BDNG - Policy to practice | BDNG - Policy to practice | BDNG - Policy to practice | BDNG - Policy to practice |
| Charter 3             |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Charter 4             |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Charter 5             |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Exchange 1            |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Exchange 2            |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Exchange 3            |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Exchange 4            |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Exchange 5            |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Exchange 6            |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Exchange 7            |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Central Room 3        |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Central Room 4        |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Central Room 5        |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Central Room 6        |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Central Room 7        |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| Central Room 8        |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |                           |
| KEY                   | BAD Sessions              | Special Interest Groups   | Exhibition / Posters      | BAD Committee             | Focus Session             | Additional Groups         | Non-BAD Meetings          | Satellite Symposia        | Delegate Information      | BDNG Session              |                           |                           |

# WEDNESDAY 7TH JULY – OVERVIEW

# WEDNESDAY JULY 7TH – DETAILED PROGRAMME

| TIME                 | CODE        | PROGRAMME  | VENUE                      |
|----------------------|-------------|--|----------------------------|
| 08:00 – 18:00        |             | Registration desk open   | Central Foyer              |
| 08:45 – 10:00        |             | <b>Scientific Session – Submitted Papers</b>   | Exchange Auditorium        |
|                      | CHAIRS      | Dr Robert Chalmers & Dr Ian Coulson  |                            |
| 08:45                | <b>O-08</b> | <b>A retrospective study of methotrexate for moderate-to-severe atopic eczema</b><br><i>S.J. Meggitt, C. Smith, G. Petrof and N.J. Reynolds</i>  |                            |
| 09:00                | <b>O-09</b> | <b>Audit of the clinical use of the thiopurine methyl transferase and thiopurine metabolite assays in the treatment of patients with azathioprine</b><br><i>A.V. Anstey, V. Graham, S. Mould, N. Barlow and J. Berg</i>  |                            |
| 09:15                | <b>O-10</b> | <b>Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: the value of an oral scoring methodology for monitoring therapeutic response</b><br><i>J.S. Wee, P.J.S. Shirlaw, S.J. Challacombe and J.F. Setterfield</i>   |                            |
| 09:30                | <b>GL03</b> | Guest Lecture – Introduced by Dr Stephen Jones<br><b>Update on cutaneous side effects of chemotherapy</b><br>Professor Jean Bologna (New Haven, USA)   |                            |
|                      |             |  <p>The lecture will focus on three topics:</p> <ul style="list-style-type: none"> <li>(1) the cutaneous side effects of epidermal growth factor receptor (EGFR) inhibitors, in particular the papulopustular eruption and its treatment;</li> <li>(2) the mucocutaneous side effects of multi-kinase inhibitors, focusing on imatinib; and</li> <li>(3) the unifying concept of toxic erythema of chemotherapy.</li> </ul> |                            |
| 10:00 – 11:00        |             | Coffee & Poster Viewing  | Central 2, Exhibition Hall |
| 11:00 – 13:00        |             | <b>Annual General Meeting (members only)</b>   | Exchange Auditorium        |
| 13:00 – 14:30        |             | Lunch & Exhibition   | Central 2, Exhibition Hall |
| <b>13:15 – 14:15</b> |             | <b>JANSSEN CILAG SATELLITE SYMPOSIUM (PAGE 57)</b>   | <b>EXCHANGE HALL</b>       |
| <b>13:15 – 14:15</b> |             | <b>LA ROCHE POSAY SATELLITE SYMPOSIUM (PAGE 57) CHARTER 3,4,5</b>  |                            |

**14:30 – 18:00**      **BRITISH SOCIETY FOR DERMATOLOGICAL SURGERY**      **EXCHANGE HALL**

**14:30 – 18:00**      **BRITISH PHOTODERMATOLOGY GROUP**      **CENTRAL 5,6,7**

|               |  |                            |
|---------------|--|----------------------------|
| 14:30 – 15:30 | <b>Scientific Session – Medical Dermatology &amp; Submitted Papers</b>   | Exchange Auditorium        |
|               | CHAIRS Prof Nick Reynolds & Dr John O’Driscoll   |                            |
| 14:30         | <b>MD01 What’s new in Immuno-bullous Diseases</b><br>Dr Richard Groves (London)  |                            |
| 15:00         | <b>O-11 A case series of 16 patients treated with rituximab for refractory immunobullous disease</b><br><u>C.L. Martyn-Simmons</u> , M. Saha, M.M. Black and R.W. Groves   |                            |
| 15:15         | <b>O-12 Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need and a chance to intervene</b><br><u>J.M.R. Goulding</u> , C.L. Price, C.L. Defty, C.S. Hulangamuwa, E. Bader and I. Ahmed |                            |
| 15:30         | <b>MD02 Polycystic Ovary Syndrome</b><br>Professor Adam Balen (Leeds)  |                            |
| 16:00 – 16:30 | Tea & Exhibition   | Central 2, Exhibition Hall |
| 16:30 – 18:15 | <b>Scientific Session – Medical Dermatology &amp; Submitted Papers Continued...</b>  | Exchange Auditorium        |
|               | CHAIRS Dr Eileen Parry & Dr Jane Sterling  |                            |
| 16:30         | <b>MD03 Dermatological aspects of HIV and an update on the issues around testing</b><br>Dr David Paige (London)  |                            |
| 17:00         | <b>O13 Hypopigmented mycosis fungoides: a study of the clinicopathological, immunophenotypic and prognostic features</b><br><u>E.C. Benton</u> , A.M. Robson and E.M. Wain   |                            |
| 17:15         | <b>O-14 The incidence of second primary skin cancer in an English region</b><br><u>A. Pring</u> , J. Verne and D.A.R. de Berker  |                            |
| 17:30         | <b>MD05 Emergency Dermatology</b><br>Dr Cameron Kennedy (Bristol)  |                            |
| 18:00         | <b>MD06 e-dermatology: BAD and e-LfH launch their joint e-learning project</b><br>Dr Robert Charles-Holmes (Warwick) & Dr Jane Sterling (Cambridge)  |                            |
| 18:15         | <b>e-dermatology launch reception</b>  | Exchange 3                 |

**WEDNESDAY 7TH JULY – DETAILED PROGRAMME**

|               |             |  |                      |
|---------------|-------------|--|----------------------|
| 14:30 – 16:30 |             | Joint Session – British Association of Dermatologists and British Dermatological Nursing Group | Charter 3,4,5        |
|               | CHAIRS      | Dr Harvinder Ghura & Sheila Robertson  |                      |
| 14:30         | <b>JM01</b> | <b>Top tips - Psoriasis and the biologics</b><br>Dr David Burden (Glasgow)                     |                      |
| 14:50         | <b>JM02</b> | <b>Top tips for PDT</b><br>Paula Oliver (Worthing)   |                      |
| 15:10         | <b>JM03</b> | <b>Top tips Paediatrics</b><br>Dr Tim Clayton (Manchester)                                     |                      |
| 15:30         | <b>JM04</b> | <b>Top tips for treating hyperhidrosis</b><br>Tracey Wheeler (Bristol)                         |                      |
| 15:50         | <b>JM05</b> | <b>Top tips Surgery</b><br>Dr Harvinder Ghura (Manchester)                                     |                      |
| 16:10         | <b>JM06</b> | <b>Top tips for treating lymphoedema</b><br>Elizabeth Coveney (Swansea)                        |                      |
| 19:30 – 00:00 |             | Annual Dinner  | Manchester Town Hall |

# WEDNESDAY 7TH JULY – BRITISH SOCIETY FOR DERMATOLOGICAL SURGERY

| TIME          | PROGRAMME  | VENUE           |
|---------------|--|-----------------|
| 14:30 – 18:00 | BRITISH SOCIETY FOR DERMATOLOGICAL SURGERY   | EXCHANGE HALL   |
| 14:30 – 15:50 | Session 1  |                 |
| CHAIR         | Dr Graeme Stables  |                 |
| 14:30         | <b>DS01 – Basal cell carcinomas excision margins: primary vs. secondary care</b><br><u>A. Alsharqi</u> , N. Wilson and P. De Mozzi   |                 |
| 14:40         | <b>DS02 – Melanocytic lesions of unknown malignant potential: features and outcome in 35 patients</b><br><u>H. Al-Rawi</u> , A. Husain and C.M. Lawrence   |                 |
| 14:50         | <b>DS03 – A traumatic pseudoaneurysm of the superficial temporal artery referred as a lipoma</b><br><u>G. Segal-Hall</u> , R. Turner and R. Asher  |                 |
| 15:00         | <b>DS04 – The Imre and perialar crescentic advancement flaps for the reconstruction of upper cheek defects and those involving the nasal sidewall and/or dorsum</b><br><u>W. Hussain</u> , E. Tan, N. Mortimer, C. Gleeson and P. Salmon |                 |
| 15:10         | <b>DS05 – The utility of the transposition-rotation flap of Weerda for the reconstruction of complex auricular defects</b><br><u>W. Hussain</u> , C. Gleeson, N. Mortimer and P. Salmon  |                 |
| 15:20         | <b>DS06 – A novel application of the W-plasty transposition flap for defects of the anterior temple</b><br><u>H. Al-Rawi</u> and J.A.A. Langtry  |                 |
| 15:26         | <b>DS07 – Free cartilage grafts to repair ala nasi defects: with concurrent skin graft or secondary intention healing</b><br><u>J. Shelley</u> , C. Lawrence and J.A.A. Langtry  |                 |
| 15:32         | <b>DS08 – Three cases of linear basal cell carcinoma treated by Mohs micrographic surgery</b><br><u>G. Becher</u> , A. Affleck, C.J. Fleming and A.E. Evans  |                 |
| 15:38         | <b>DS09 – Collapse during scalp tumour extirpation: a cautionary tale for the Mohs micrographic surgeon</b><br><u>W. Hussain</u> , P. Salmon, C. Gleeson and N. Mortimer   |                 |
| 15:44         | <b>DS10 – Case report and video demonstration of bilateral symmetric transposition flap to treat a challenging basal cell carcinoma on the forehead</b><br><u>R. Verdolini</u> , N. Clayton and C.L. Lowry                               |                 |
| 15:50 – 16:20 | Break  | Exhibition Hall |

- 16:20 – 16:50 Session 2 Joint Session BSDS / BCDG Exchange Hall
- CHAIRS Dr Raj Mallipeddi & Dr Tamara Griffiths
- 16:20 **DS11 – A study of the efficacy of carbon dioxide and pigment-specific lasers in the treatment of medium-sized congenital melanocytic naevi**  
V. Madan, J. Ferguson and P.J. August
- 16:26 **DS12 – Hairy intraoral flap: an unusual indication for laser depilation**  
T.N. Shim, N. Talsania, K. Chittari, C. Avery, S. Lanigan and A. Abdullah
- 16:32 **DS13 – The increasing use of fat grafting**  
S. Tzortzis and V. Vijh
- 16:38 **DS14 – Botulinum toxin A for focal hyperhidrosis of the face and amputation stump**  
L. Atkinson, S. George and B. Shergill
- 16:44 **DS15 – Plication of the superficial musculoaponeurosis facilitates tension-free closure of medium- to large-sized defects on the temple and cheek**  
R.R. Rahim, R.B.M. Barry and T.H. Nguyen
- 16:50 – 17:40 Session 3
- CHAIR Dr Sandeep Varma
- 16:50 **DS16 – The use of printed digital photographs as a substitute for conventional schematic Mohs maps: our experience of 80 cases**  
B. Moriarty, F. Deroide and E.D. Seaton
- 16:56 **DS17 – Comparison of ex vivo optical coherence tomography with conventional frozen-section histology for visualizing basal cell carcinoma during Mohs micrographic surgery**  
D. Cunha, T. Richardson, N. Sheth, G. Orchard, A. Coleman and R. Mallipeddi
- 17:02 **DS18 – Mohs micrographic surgery in a U.K. teaching hospital: audit of the first 6 years (2003–09) and introduction of a new minimum dataset**  
A. Waters, L. Macfarlane, A.E. Evans, A. Affleck and C.J. Fleming
- 17:08 **DS19 – Mohs micrographic surgery for dermatofibrosarcoma protuberans**  
S. Rajpara, S. Varma, G. Perks and W. Perkins
- 17:14 **DS20 – Mohs micrographic surgical excision for atypical fibroxanthoma at critical sites**  
R.R. Rahim and J.A.A. Langtry
- 17:20 **DS21 – Salvage Mohs micrographic surgery for highly destructive facial nonmelanoma skin cancer. Is it of benefit?**  
B. Wynne, M. McMenamin, C. Timon and P. Ormond
- 17:26 **DS22 – Meticillin-resistant Staphylococcus aureus prevalence in a Mohs micrographic surgery service**  
A. Foulkes, S. Dunn, C.M. Lawrence and J.A.A. Langtry
- 17:32 **DS23 – Mohs micrographic surgery for dermatofibrosarcoma protuberans: experience in a large regional centre**  
W.P. Tan, J. Mckenna, A. Robson and R. Mallipeddi
- 18:00 – 18:30 BSDS AGM Exchange Hall

Posters

**DS24 – Successful treatment of pulsed dye laser recurrent granuloma faciale with the carbon dioxide laser**

V. Madan and P.J. August

**DS25 – Adenoid cystic carcinoma vs. adenoid basal cell carcinoma: a Mohs challenge**

L.E. Proudfoot, I. Roxanis and S. Bashir

**DS26 – Audit: infection rates following dermatological surgery**

A. Fogo and S. Bashir

**DS27 – Follow-up preferences for patients with basal cell carcinoma: the basis for modelling clinical practice and commissioning**

D.A.R. de Berker, V. Poirier and A. Takwale

**DS28 – Audit of 2-week-wait referrals: how does tertiary referral influence management?**

S. Anthony, C. Vlachou, M. Murdoch, F. Tatnall, K. Batta and V. Brown

**DS29 – Do skin cancer multidisciplinary teams make any difference in the management of incomplete or narrowly excised basal cell carcinomas?**

C. Kasparis, L. Yalakki and I. Ahmed

**DS30 – Serial excision: a useful technique to achieve good cosmetic outcomes when excising large benign naevi**

S. Ng, V. Madan and A. Morris

**DS31 – A proof of concept study to investigate the efficacy of microneedle arrays in local anaesthetic administration to human skin**

M.A. McAleer, A. Moore, A. Crean, C. O'Mahoney and J. Bourke

**DS32 – Malignant cytology in washings of Mohs micrographic surgery instruments**

B. Moran, B. Wynne, S. Thomas, M. Griffin, M. McMenemy and P. Ormond

**DS33 – Dermatological surgery in the community: are the guidelines being followed?**

M.G. Khorasgani, S. Payne and M. Khorshid

**DS34 – Toluidine blue in Mohs surgery: another indication and its advantage in a case of a primary morphoeic basal cell carcinoma coexisting with B-cell marginal zone lymphoma**

K. Chittari, I. Leach, W. Perkins and S. Varma

**DS35 – Rhinophyma and basal cell carcinoma**

R. Kwah and C.M. Lawrence

**DS36 – Closure of combined nasal ala-perialar defect with the Shark Island pedicle flap**

R. Kwah and J.A.A. Langtry

**DS37 – Swab technique**

A. Foulkes, M. Narayanan, J.A.A. Langtry and C.M. Lawrence

**DS38 – The head-tilt manoeuvre**

V. Madan and P.J. August

**DS39 – Superficial parotidectomy and the use of silastic sheet: a potential method to protect against buccal nerve and parotid duct injury during Mohs surgery for mid cheek skin cancer**

K. Chittari, A. Graeme Perks and W. Perkins

# WEDNESDAY JULY 7TH BRITISH – PHOTODERMATOLOGY GROUP

| TIME | PROGRAMME | VENUE |
|------|-----------|-------|
|------|-----------|-------|

|               |                                |               |
|---------------|--------------------------------|---------------|
| 14:30 – 18:00 | BRITISH PHOTODERMATOLOGY GROUP | CENTRAL 5,6,7 |
|---------------|--------------------------------|---------------|

|        |  |                 |
|--------|--|-----------------|
| CHAIRS | Prof Anthony Young & Dr David Taylor   |                 |
| 14:30  | <b>Is UVR-induced immunosuppression of clinical significance?</b><br>Professor Mary Norval   |                 |
| 15:05  | <b>UVA and the heart. Is NO news good news?</b><br>Dr Richard Weller   |                 |
| 15:40  | <b>PD01 – Xeroderma pigmentosum presenting without any abnormal sunburn reactions: first correlation between complementation group and acute effect of sunlight</b><br><u>H. Fassihi</u> , S. Walker, D. McGibbon, H. Fawcett, A. Lehmann and R. Sarkany |                 |
| 15:55  | <b>PD02 – UVA1 phototherapy: the experience of one centre</b><br><u>S. Attili</u> , R.S. Dawe, S. Ibbotson and J. Ferguson   |                 |
| 16:10  | Tea & Coffee Break   | Exhibition hall |
| CHAIRS | Prof Anthony Young & Dr David Taylor   |                 |
| 16:45  | <b>PD03 – The melanocyte stimulating hormone analogue afamelanotide conveys photoprotection in solar urticaria</b><br><u>A.K. Haylett</u> , Z. Nie, M. Brownrigg, R. Taylor and L.E. Rhodes  |                 |
| 17:00  | <b>PD04 – Solar urticaria confined to areas of bruising</b><br><u>B. Esdaile</u> , S.A. Grabczynska and S. George  |                 |
| 17:15  | <b>PD05 – Solar urticaria: an analysis of trends and treatment efficacy in the Irish population</b><br><u>S.M. Verma</u> , L. Gaynor and G.M. Murphy   |                 |
| 17:30  | <b>PD06 – Sealed-unit semiautomated minimum erythema dose (MED) testers allow for safe and convenient MED testing prior to ultraviolet B phototherapy</b><br><u>R.Y.P. Hunasehally</u> , A.V. Anstey and C. Edwards                                      |                 |
| 17:45  | Close of meeting   |                 |



Posters

**PD07 – Familial porphyria cutanea tarda associated with the HFE gene mutation**

M. Lynch, A. Ryan and P. Collins

**PD08 – Treatment of cutaneous sarcoid with topical gel photochemotherapy**

I. Staveley, C. Gleeson, N. Morar and C. Bunker

**PD09 – Comparative efficacy of photochemotherapy and narrow band ultraviolet B radiation in the treatment of severe plaque type psoriasis**

V. Malhotra

**PD10 – A rarely reported cause of drug-induced photoaggravated eczema**

F. Al-Niaimi and C.C. Lyon

**PD11 – Bath psoralen plus ultraviolet A for hidradenitis suppurativa: a review of 13 patients**

M.S. Shareef and R.S. Dawe

**PD-12 – Comparison of clinical efficacy and cost-effectiveness of photochemotherapy vs. photochemotherapy with natural sunlight in chronic plaque psoriasis in Indian patients**

S. Khandpur, K. Aggarwal, N. Khanna, V.K. Sharma and C.S. Pandav



# THURSDAY 8TH JULY – OVERVIEW

| Thursday 8th July   | 07:30 - 8:00      | 08:00 - 09:00                      | 09:00 - 10:00                 | 10:00 - 11:00 | 11:00 - 12:00           | 12:00 - 13:00              | 13:00 - 14:00                         | 14:00 - 15:00       | 15:00 - 16:00        | 16:00 - 17:00 | 17:00 - 18:00 | 18:00 - 19:00 |
|---------------------|-------------------|------------------------------------|-------------------------------|---------------|-------------------------|----------------------------|---------------------------------------|---------------------|----------------------|---------------|---------------|---------------|
| Exchange Auditorium |                   |                                    | Professors & Registrars Forum |               | Prof & Registrars Forum | Guest Lecture Rook Oration |                                       |                     | CPD Session          | Guest Lecture | CPD Session   |               |
| Central Foyer       | Registration Open |                                    |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Central Hall 2      | Exhibition        |                                    |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Exchange Hall       |                   |                                    |                               |               |                         |                            | Satellite Symposium Sclerating Plough |                     |                      |               |               |               |
| Charter 3           |                   |                                    | BDNG Advanced Programme       |               | BDNG Advanced Programme |                            |                                       |                     |                      |               |               |               |
| Charter 4           |                   |                                    |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Charter 5           |                   |                                    |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Exchange 1          |                   |                                    |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Exchange 2          | CMF Breakfast     |                                    |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Exchange 3          |                   |                                    |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Exchange 4          |                   | Exhibitors Meeting                 |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Exchange 5          |                   |                                    |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Exchange 6          |                   | UK DCTN Trial Prioritisation Panel |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Exchange 7          |                   | BSF Grants Advisory                |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Central Room 3      |                   |                                    |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Central Room 4      |                   |                                    |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Central Room 5      |                   |                                    |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Central Room 6      |                   |                                    |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Central Room 7      |                   |                                    |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| Central Room 8      |                   |                                    |                               |               |                         |                            |                                       |                     |                      |               |               |               |
| KEY                 | BAD Sessions      | Special Interest Groups            | Exhibition / Posters          | BAD Committee | Focus Session           | Additional Groups          | Non-BAD Meeting                       | Satellite Symposium | Delegate Information | BDNG Session  |               |               |

# THURSDAY 8TH JULY – OVERVIEW

# THURSDAY 8TH JULY – DETAILED PROGRAMME

| TIME                 | CODE        | PROGRAMME   | VENUE                      |
|----------------------|-------------|---|----------------------------|
| 08:00 – 18:00        |             | Registration desk open  | Central Foyer              |
| <b>08:30 – 12:15</b> |             | <b>Professors &amp; Registrars Forum</b>  | <b>Exchange Auditorium</b> |
| 08:30 – 10:25        | CHAIRS      | Dr Richard Groves & Prof Eugene Healy   |                            |
| 08:30                | <b>RF01</b> | <b>Panton–Valentine leucocidin (PVL)-positive Staphylococcus aureus cause recalcitrant skin infections in dermatology patients</b><br>A. Fogo, <u>E. Craythorne</u> , J. Wade, R. Hay and R. Morris-Jones   |                            |
| 08:45                | <b>RF02</b> | <b>Clinical and genetic predictors of treatment response to narrowband ultraviolet B radiation for chronic plaque psoriasis</b><br>C. Ryan, <u>P. Collins</u> , B. Kirby and S. Rogers  |                            |
| 09:00                | <b>PR01</b> | <b>Translational research in photodermatology</b><br>Professor Alex Anstey (Newport)  |                            |
| 09:20                | <b>RF03</b> | <b>Response to hydroxychloroquine in patients with discoid lupus erythematosus</b><br><u>S. Wahie</u> , M. Goodfield, A.J. Carmichael, M.M. Carr, A. Drummond, S.K. Jones, C.R. Lovell, N. Reynolds and S.J. Meggitt  |                            |
| 09:35                | <b>RF04</b> | <b>IgA from two patients with erythema elevatum diutinum associated with IgA antineutrophil cytoplasmic antibody stimulates superoxide production and degranulation of neutrophils in vitro</b><br><u>R. Simpson</u> , S.J. Alvaro, M. Morgan, A.B. Alexandroff, C. Savage, J. Williams and K.E. Harman |                            |
| 09:50                | <b>PR02</b> | <b>Academe</b><br>Professor Christopher Griffiths (Manchester)  |                            |
| 10:10                | <b>RF05</b> | <b>Functional failure of lymphatics in human primary melanoma</b><br><u>V. Akhras</u> , R. Ramakrishnan, A. Stanton, R. Mellor, R. Levick and P.S. Mortimer   |                            |
| 10:25 – 11:10        |             | Coffee & Exhibition   | Central 2, Exhibition Hall |
|                      |             | <b>Professors &amp; Registrars Forum continued...</b>   |                            |
| 11:10 – 12:15        | CHAIRS      | Dr Mark Goodfield & Dr Richard Warren   |                            |
| 11:10                | <b>RF06</b> | <b>HLA class II allele distribution in pemphigus foliaceus in white Europeans and Indo-Asians from the U.K.</b><br><u>M. Saha</u> , K.E. Harman, N.J. Mortimer, V. Bind, M.M. Black, E. Kondeatis, R. Vaughan and R.W. Groves   |                            |
| 11:25                | <b>PR03</b> | <b>Genodermatoses</b><br>Professor Edel O’Toole (London)  |                            |

- 11:45 **RF07** **Cutaneous Lymphoma International Prognostic Index (CLIP1)**  
E.C. Benton, S. Crichton, N.S. Agar, P. Fields, E. Wedgeworth, T.J. Mitchell,  
 M. Cox, S. Ferreira, A.M. Robson, E. Calonje, C.M. Stefanato, E.M. Wain,  
 B. Wilkins, A. Dean, K. Webb, J. Scarisbrick, S. Morris and S.J. Whittaker
- 12:00 **RF08** **BSID Best paper:**  
**Dysregulated tropomyosin receptor kinase (Trk) signalling in**  
**CYLDtrunc/trunc tumours**  
N Rajan, CJ Lord, O Clewes, J Burn, M Sieber-Blum and A Ashworth
- 12:15 **GL04** **Arthur Rook Oration**  
 Guest Lecture – Introduced by Dr Stephen Jones  
**Neutrophilic vascular reactions**  
 Dr Joseph Jorizzo (Winston-Salem, USA)



In a 1988 CME article in the JAAD, we speculated that common aspects of pathogenesis, patient education and treatment existed for certain dermatoses characterized by neutrophilic dermal infiltrates that had previously been considered separately. Viewed 22 years later the concept of neutrophilic vascular reactions has become well accepted. Even though dramatic new research breakthroughs have been lacking, an update is warranted.

13:00 – 14:30 Lunch & Exhibition Central 2, Exhibition Hall

**13:15 – 14:15 SCHERING-PLOUGH SATELLITE SYMPOSIUM (PAGE 58) EXCHANGE HALL**

**14:30 – 18:00 Continuing Professional Development Session Exchange Auditorium**

CHAIRS Dr Robert Charles-Holmes & Dr Stephen White

14:30 – 15:00 **CPD01** **Biologics, which/when**  
 Dr Catherine Smith (London)

15:00 – 15:30 **CPD02** **Connective Tissue Diseases**  
 Dr Chris Lovell (Bath)

15:30 – 16:00 **CPD03** **CAMS (Clinical Audit Management Software) presentation**  
 Dr Claire Fuller (Canterbury)

16:00 – 16:30 **GL05** Guest Lecture – Introduced by Dr Mark Goodfield  
**Current thinking in medical education**  
 Professor Sarah Thomas (Leeds)



The lecture as part of the Continuing Professional Development session will provide an overview of the educational process including the role of the Lead Dean and the role of Medical Education England and will allow the opportunity to consider the following current topical areas in medical education:

- EWTR
- Workforce Data
- Financial constraints on health economics – 2011 onwards
- Quality Metrics
- Training interfaces between community and secondary care

16:30 – 17:00 Coffee Break Exchange Hall

CHAIRS Prof Alex Anstey & Prof Edel O’Toole

17:00 – 17:30 **CPD04** **What’s new in Photodermatology**  
 Professor Lesley Rhodes (Salford)

17:30 – 18:00 **CPD05** **Update on paediatric dermatology**  
 Dr Mary Judge (Salford)

18:00 – 18:15 **President’s Address**  
 Dr Stephen Jones (Wirral)

18:15 Close of meeting



# ADDITIONAL MEETINGS

## TUES 6TH JULY

| TIME          | MEETING   | ROOM              |
|---------------|---|-------------------|
| 10:00 – 12:00 | <b>British Teledermatology Society</b><br>For further information please contact:<br>Saul.Halpern@medway.nhs.uk | <b>Exchange 3</b> |
| 17:30 – 18:30 | <b>Dermatology Teachers</b><br>Expert lecture series launch<br>E-learning programme for dermatology<br>AOB      | <b>Central 6</b>  |

## WED 7TH JULY

| TIME          | MEETING   | ROOM              |
|---------------|---|-------------------|
| 13:00 – 14:00 | <b>British Society for Medical Dermatology Committee Meeting</b>                          | <b>Exchange 1</b> |
| 17:00 – 18:30 | <b>Senior Skin Group</b><br>For further information please contact maggie@kirkup.plus.com | <b>Exchange 4</b> |
| 18:15 – 19:00 | <b>e-dermatology Launch Reception</b>   | <b>Exchange 3</b> |

## THURS 8TH JULY

| TIME          | MEETING   | ROOM                  |
|---------------|---|-----------------------|
| 07:30 – 08:30 | <b>Christian Medical Fellowship</b><br>If you would like to reserve a place at the breakfast<br>please contact: conference@bad.org.uk | <b>Exchange 2 / 3</b> |



## POSTERS

The posters are situated within the exhibition area Central 2 and there will be a dedicated poster viewing hour on **Wednesday July 7th from 10:00 – 11:00**. All presenting authors have been asked to stand by their poster at this time.

## BRISTOL CUP POSTERS

### Case series and cases / CPCs

- P-1 Cutaneous leiomyoma: the dermatological presentation of hereditary leiomyomatosis and renal cell cancer**  
M. Durkie, R. Pollitt, L. Chapman, A. Dalton and G. Sobey
- P-2 An unusual first presentation of Darier disease with psychosis and myositis**  
K.W. Tan and R.S.P. Lim
- P-3 Axillary (and facial) acne agminata mimicking hidradenitis suppurativa**  
A. Martin, G. Becher and G. Dawn
- P-4 Review of patients with dual diagnosis of vulval lichen planus and vulval lichen sclerosis (lichen sclerosis/lichen planus overlap)**  
C.M. Green, J. Gibbs, J. Guest and J. Paterson
- P-5 Disseminated superficial actinic porokeratosis treated effectively with topical imiquimod 5% cream**  
B. Arun, J.M. Pearson and R.J.G. Chalmers
- P-6 Incontinentia pigmenti and squamous cell cancer**  
J. Mikeljevic and C.C. Lyon
- P-7 Microspheeropsis arundinis: a rare cause of cutaneous infection**  
T.N. Win, T. Chave and E. Johnson
- P-8 Idiopathic hyperkeratosis of nipple and areola**  
R. Fatima and G. Dawn
- P-9 A family with Fabry disease diagnosed by a single angiokeratoma**  
A. Corry, C. Feighery, D. Alderdice, F. Stewart, M. Walsh and O.M. Dolan
- P-10 Lacrimal canalicular duct scarring in patients with lichen planus**  
N.K. Webber, F.M. Lewis, J.F. Setterfield and S. Neill
- P-11 An unusual cause of neonatal scarring**  
J. Felton and C.R. Darley
- P-12 Familial pemphigus vulgaris**  
M. Saha, M.M. Black, B. Bhogal and R.W. Groves
- P-13 Atypical cutaneous lymphoproliferative disorder, the presenting feature of a patient subsequently diagnosed with human immunodeficiency virus infection**  
L. Stewart, Z. Twaji and C. Owen
- P-14 An unusual cause of alopecia, rash and retinitis**  
J. Felton, L. Atkinson and C. Degiovanni
- P-15 Sniffing out bed bugs: a clinical case and update**  
J. Felton and L. Atkinson

- P-16 A case series of three patients with erythema elevatum diutinum in association with paraproteinaemia and IgA antineutrophil cytoplasmic antibodies**  
R. Simpson, S.M. Crichlow, A.B. Alexandroff and K.E. Harman
- P-17 Howel-Evans syndrome: cutaneous presentation associated with internal malignancy**  
N.Y.Z. Chiang and J. Verbov
- P-18 A case-control study demonstrating drug associations in patients diagnosed with bullous pemphigoid**  
A. Lloyd-Lavery, K. Taghipour and F.T. Wojnarowska
- P-19 A rare cause of panniculitis requiring a novel therapy**  
F. Al-Niaimi and C.C. Lyon
- P-20 A case of unilateral leg ulcers secondary to Brown-Sequard syndrome**  
J.S. Wee, L. Yeo, G. Petrof, S.M. Langan and C.H. Smith
- P-21 First report of lichen sclerosus in three successive generations**  
S.K. Goolamali, S.I. Goolamali and H. Gordon
- P-22 Schöpf-Schulz-Passarge syndrome: a case report**  
T. Patel and S. Loghdey
- P-23 Dermatitis herpetiformis arising within vitiligo in the presence of multiple autoimmune conditions**  
A.E. Macbeth, L. Igali, N.J. Levell and G.W.M. Millington
- P-24 Lichen planopilaris following hair transplantation and facelift surgery**  
L. Lyne, M.J. Harries, I.H. Chaudhry, B. Farjo, N. Farjo, D. Cadore de Farias, A. Tosti, C.E.M. Griffiths and R. Paus
- P-25 Severe penile lymphoedema complicating hidradenitis suppurativa: two cases**  
N. Desai, G. Petrof, E. Healy and P.S. Mortimer
- P-26 Localized scleroderma (morphoea) with retinal and cerebral involvement**  
J. Kluk and J. Bhat
- P-27 Morphoea secondary to radiation injury**  
J. Crawley, M.Y. Walsh and K.E. McKenna
- P-28 A review of orofacial granulomatosis in a specialist dermatology/oral medicine clinic**  
P.D. Yesudian, B.P. Rajlawat and E.A. Field
- P-29 Neurofibromatosis type 1 with extensive cutaneous disease burden and dysmorphic features caused by complete gene deletion: a specific subtype requiring close surveillance**  
E. Higgins, B. Cullen, M. Bennett and P.A. Marren
- P-30 Recessive inheritance of mild epidermolysis bullosa simplex**  
W. Szczecinska, A. Terron-Kwiatkowski, D. Baty and C. Moss
- Education & Training**
- P-31 Future proofing clinical meetings: demonstrating educational efficacy**  
A. Weidmann, T.P. Kingston and M. Singh
- P-32 Dermacademy: a unique e-learning tool for dermatology clinicians**  
A.A. Atwan and M.L. Gonzalez
- P-33 Learning dermatology: how can we do it better?**  
M. Singh, L.E. Rhodes and T. Dornan

- P-34 Integrating computer assisted instruction in traditional undergraduate dermatology promotes adult learning**  
R. Gamanya and B. Stephen
- P-35 Assessments of trainees: still an evolving process?**  
G. Wylie and A. Drummond
- P-36 Does undergraduate dermatology education affect junior doctors' diagnostic and therapeutic skills?**  
B. Zafiri and P.D. Yesudian

### Inflammatory Skin Diseases

- P-37 Many patients with psoriasis need long-term specialist dermatology care**  
C. Kwok and M. Shah
- P-38 Does incidence of male genital dermatoses vary with age?**  
M. Shah
- P-39 Assessing quality of life of family members of patients with inflammatory skin diseases using two preference-based measures**  
O. Williams and M.K.A. Basra
- P-40 Abstract withdrawn**
- P-41 Severe psoriasis has a greater negative effect on quality of life than previously appreciated: a U.K. web-based patient survey**  
A.V. Anstey, G. Edwards and A. Lass
- P-42 Ets-1 transcription factor and matrix metalloproteinases: critical role in repigmentation of vitiligo**  
D. Parsad, R. Kumar and A.J. Kanwar
- P-43 Measuring the severity and impact on quality of life of infants with atopic dermatitis in a dedicated clinic**  
K. Ahmad, J. Saunders and B.C.P. Ramsay
- P-44 The influence of chronic skin diseases on major life-changing decisions as a parameter for the assessment of long-term impact**  
Z.U. Bhatti, S. Salek and A.Y. Finlay
- P-45 The patient experience: a survey of members of the Psoriasis Association**  
G. Edwards, A.K. Gilbert and H. McAteer
- P-46 Validation of a psoriatic arthritis screening questionnaire in rheumatology and dermatology outpatients**  
C. Marshall, M. Bukhari and P.V. Harrison
- P-47 Strengthening the Dermatology Life Quality Index's clinical meaning: minimal clinically important difference of the scores**  
M.K.A. Basra, L. Camilleri, S. Salek and A.Y. Finlay
- P-48 Localized staphylococcal scalded skin syndrome in five patients with atopic dermatitis**  
S.I. Goolamali, C. Haddadeen, J.D. Creamer, R. Hay, E.M. Higgins and R. Morris-Jones
- P-49 Extradomain A-positive fibronectin positive feedback loops in psoriasis**  
J. McFadden, B. Baker, A. Powles and L. Fry
- P-50 Patch testing for peristomal dermatitis among patients with a stoma: results of our 10 years' experience**  
F. Al-Niimi and C.C. Lyon

- P-51 Early maladaptive schemas and psychological distress in outpatients with psoriasis and atopic eczema**  
A. Mizara, L. Papadopoulos and S.R. McBride
- P-52 Dose rate-dependent upregulation of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 by ultraviolet A in human keratinocytes**  
J. Whiteside, A. Ridley, T.J. McMillan, S. Allinson and S. Long
- P-53 Cicatricial alopecias: a retrospective analysis of 92 cases from one U.K. centre**  
M.J. Harries, I.H. Chaudhry, R. Paus and C.E.M. Griffiths

### Medical Dermatology & Therapy

- P-54 A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment vs. laser treatment alone for facial hirsutism in women**  
M. Arora
- P-55 Nonclinical influences in dermatology decision making: a study of clinicians' perspective**  
F. Hajjaj, S. Salek, M.K.A. Basra and A.Y. Finlay
- P-56 Refractory aphthous ulceration treated with thalidomide: a report of 10 years' clinical experience**  
S. Cheng, V. Smith and R. Murphy
- P-57 Simple, effective keloid surgery within the dermatology department**  
D. Odunsi and R. Morris-Jones
- P-58 Interventions for vitiligo: a Cochrane systematic review**  
M. Whitton, M. Pinart, J. Batchelor, C. Lushey, J. Leonardi-Bee and U. Gonzalez
- P-59 A 'real world' observational study of adalimumab in patients with moderate to severe psoriasis who have failed on etanercept therapy: a retrospective case cohort study**  
R. Woolf, K. Robertson, C.H. Smith and J.N.W.N. Barker
- P-60 Efficacy and safety of acitretin in three fixed doses of 25 mg, 35 mg or 50 mg in patients with severe plaque-type psoriasis: a randomized, double-blind, parallel-group, dose-ranging study**  
S. Dogra, A. Jain and I. Kaur
- P-61 Old problem, new technique: introducing a novel bandaging technique for the management of lower leg ulceration**  
S. Wong, R. Bull, A. Hopkins, M. O'Brien, F. Worboys, I. Farrelly and W. George
- P-62 Paradoxical induction of psoriasis by antitumour necrosis factor therapy: a case series**  
T. Patel, V. Ghura, A. Messenger, P. Marks and H. Ramsay
- P-63 Attitudes towards use of topical treatments during Ramadan: perspective of U.K. Muslim patients**  
T. Patel and V. Ghura
- P-64 Dapsone as adjuvant treatment in chronic ordinary urticaria: positive implications for quality of life**  
N. Rajan, S. Darne, A. Ah-Weng and A.J. Carmichael
- P-65 Chronic truly idiopathic urticaria and autoimmune urticaria: are they the same?**  
S. Yadav, A.J. Kanwar, D. Parsad and R.M. Walker
- P-66 Ustekinumab safety update: cumulative experience from longer-term follow-up of patients treated in the ustekinumab psoriasis clinical development programme**  
 K. Gordon, C. Leonardi, C.E. Griffiths, P.O. Szapary, N. Yeilding, M.C. Hsu, N. Wasel, J. Prinz and K. Reich

- P-67 Mucous membrane pemphigoid successfully treated with the combination of mycophenolate mofetil and dapsone**  
H. Al-Rawi, K.S. Staines and P.J. Hampton
- P-68 Preliminary studies to inform the STOPGAP trial: how the pilot work influenced the main trial design**  
F. Craig, A.D. Ormerod, K. Thomas and H. Williams
- P-69 Ustekinumab in patients with psoriasis who have failed all other biologic agents**  
W. Malik and M.J.D. Goodfield
- P-70 Effectiveness of parenteral methotrexate in recalcitrant dermatoses: a worthwhile consideration prior to biologics?**  
P.D. Yesudian
- P-71 High-performance liquid chromatography assay for the detection of diphencyprone and the metabolite diphenylacetylene in serum and urine following topical application for the treatment of alopecia areata**  
Y. Mukasa, A. Drbal, N. Anyakoha, D. Fairhurst, S.P. Macdonald Hull and A. Nicolaou
- P-72 Successful treatment of severe chronic urticaria with omalizumab**  
H. Fassihi, J.M. White, E. Benton, G. Morgan, M.W. Greaves and C.E.H. Grattan

### Melanoma & Skin Cancer

- P-73 An audit of melanoma referrals from general practitioners to a district general hospital dermatology department**  
P. Kerr, M. Clement, C. Powell and S. Munn
- P-74 How does melanoma recurrence present? Findings from the North Wales melanoma database**  
D. Shah, A. Sarpal and R. Lister
- P-75 Sunscreen use and availability in the U.K.: a cost-based analysis**  
C. Wilkinson and T. Lucke
- P-76 Sunnier European countries have a lower melanoma mortality**  
A.R. Shipman and N.J. Levell
- P-77 Management of cutaneous melanoma in primary care in the East of England**  
G. Ali, J. Garioch, E. Tan, C. Waddy, M. Moncrieff, S. Gibbs and V. Gudi
- P-78 Management and outcomes of 28 cases of Merkel cell carcinoma treated in our centre, 2003 – 2008**  
N.C. Chetty, L. Igali, M. Moncrieff and J. Garioch
- P-79 Factors associated with incomplete excision of basal cell carcinomas**  
Y.L. Teoh, S.M. Halpern and L. Shall
- P-80 Measures of ultraviolet radiation in the South West**  
C. Wilkinson, M. Saunders and A. Curnow
- P-81 Alemtuzumab-resistant Sézary syndrome responding to zanolimumab**  
V. Shpadaruk, A.B. Alexandroff, M. Bamford, M.J.S. Dyer and R. Burd
- P-82 CDKN2A and CDK4 mutations in two unrelated British melanoma-prone families and implications for genetic testing**  
J. Lai-Cheong, G. Pichert, K.M. Acland and S. Whittaker
- P-83 Analysis of copy number changes in primary cutaneous malignant melanoma, with and without metastases, by multiplex ligation-dependent probe amplification**  
A.-M. Martin, S. Lake, A. Taktak, P. Brackley, P. Hold, N. Leonard and S. Coupland

- P-84 Audit of completeness of cancer registration for basal cell carcinoma and its impact on use for quality assurance**  
I. Pignatelli, V. Poirier, D.A.R. de Berker and J. Verne
- P-85 Can healthy adults maintain sufficient vitamin D levels without ultraviolet radiation? Implications for prevention of skin cancer**  
S.A. Rice, M. Carpenter, L.M. Vearncombe, A. Fityan, J. Baird and E. Healy
- P-86 Socioeconomic status and prognostic factors in cutaneous melanoma**  
M.I. Darling, C. Leitch, D. Brewster, L.A. Bhatti, S. Jensen and V.R. Doherty
- P-87 A retrospective network study of the latest Royal College of Pathologists' minimum dataset for malignant melanoma**  
S. Pruneddu, D. Piras, U. Igbokwe, N. Wijesuriya, F. Cottoni and R. Cerio
- P-88 Single-centre retrospective review of patients with melanoma receiving whole brain radiotherapy for metastatic disease**  
S.H. Hussain, K.A. Zaki, S. Crusz and P. Corrie
- P-89 Two-week wait skin cancer referral outcomes: differences in management between plastic surgery and dermatology**  
E. Ogden and J. Schofield

### Service Issues

- P-90 The development of the National Ehlers–Danlos Syndrome Specialist Service**  
J. Bowen, J. Tocher, J. Lemmon, R. Pollitt, A. Dalton and G. Sobey
- P-91 Do dermatologists help patients? Using patient-reported outcome measures in a district general hospital**  
N. Harper, C. Sharpe, K. Horton, E. Whyles, H. Bunn, K. Shepherd and N. Hepburn
- P-92 Improving risk management in dermatology: retrospective review and prospective recommendations**  
D.J. Gawkrödger
- P-93 Evaluation of the compliance with NICE guidance on the use of biologics in the management of severe psoriasis**  
A.P. Bewley, R. Cerio, M. Clement, S. Hunt, T. Lucke, R. Ratnavel, S. Walton and S. Marshall
- P-94 Dermatitis artefacta: outcome is better with a multidisciplinary dermatology/liaison psychiatry team approach**  
P. Mohandas, A.P. Bewley and R. Taylor
- P-95 Is surgery carried out in secondary care dermatology departments a cost-efficient service?**  
M. Clement
- P-96 The national tariff fails to compensate adequately for dermatology services**  
H.M. Liew and M. Shah
- P-97 Referrals, red legs and reflective learning: a 12-month audit of inpatient dermatology referrals at a district general hospital**  
A. Weidmann, T. Griffiths and T.P. Kingston
- P-98 Low-priority procedures: do they need to be top priority?**  
J.R. Felton, L.R. Atkinson, S.M.C. George and E.K. Derrick
- P-99 Are NICE skin cancer guidelines being followed in primary care? A re-audit to review changes in practice in an inner city setting**  
P. Dewan, E. Panagou, S. Kajen, A.P. Bewley, A. Sahota and K. Gibbon

- P-100 The impact of a new model of acute care delivery on the emergency dermatology referrals**  
C. Vlachou, T. Lwin, F. Tatnall, K. Batta, M. Murdoch and J. Dyche
- P-101 Legal claims in English dermatological practice**  
S. Ong and I.H. Coulson
- P-102 Under-reporting of invasive malignant melanomas in North East of Scotland**  
F. Hussain, F. Muller and E. Husain
- P-103 Nonattendance at dermatology outpatient clinics**  
S.M.C. George, L.R. Atkinson, J.R. Felton, D.A. Harrison, E.K. Derrick and C.R. Darley
- P-104 Retrospective assessment of the diagnostic accuracy of an admitting diagnosis of cellulitis and appropriateness of antibiotic therapy**  
C.L. Defty, J.M.R. Goulding, I. Ahmed and J.E. Gach
- P-105 Two-year retrospective review of a transplant–dermatology surveillance clinic in the management of renal transplant recipients**  
V. Samarasinghe, S. Russell, V. Madan and J.T. Lear
- P-106 Full skin examination is essential in the assessment of dermatology patients: an audit of 494 patients**  
B. Moran, I. McDonald and B. Kirby
- P-107 Retrospective analysis of a psychodermatology service**  
A. Mizara and S. McBride
- P-108 Completeness of basal cell carcinoma excisions in an English region**  
I. Pignatelli, V. Poirier, D.A.R. de Berker and J. Verne
- P-109 Wound infection rates and revalidation. Who will be measuring our infection rates?**  
B. Esdaile and E. Williamson
- P-110 The impact of designated dermatology beds on the Dermatology Life Quality Index score of patients before and after their admission**  
B. Esdaile and R. Ratnavel

## History

- P-111 Sir Archibald Gray 1880–1967: founding father of the British Association of Dermatologists**  
S. Orpin
- P-112 A history of Ehlers–Danlos syndrome**  
G. Sobey and M. Shah
- P-113 The 1962 smallpox outbreak: lessons for today**  
P. Trehan, J. Wright and A. Wright

## TUESDAY JULY 6TH – SATELLITE SYMPOSIUM

| TIME          | PROGRAMME                 | VENUE         |
|---------------|---------------------------|---------------|
| 13:15 – 14:15 | PFIZER SATELLITE SYMPOSIA | EXCHANGE HALL |

### Long term management of Psoriasis

Chair Professor Jonathan Barker, London

**Long Term efficacy of biologics:  
How important is this to the long term management of Psoriasis**  
Robert Strohal, Austria

**Learning's from the biologic registry data:  
How important is the emerging safety data for the biologics**  
James Galloway, Manchester

**Psoriasis & co-morbidities:  
What are the most important co-morbidities the dermatologist  
should consider and manage**  
Richard Warren, Manchester

## TUESDAY JULY 6TH – SATELLITE SYMPOSIUM

| TIME          | PROGRAMME                 | VENUE         |
|---------------|---------------------------|---------------|
| 13:15 – 14:15 | ABBOTT SATELLITE SYMPOSIA | CHARTER 3,4,5 |

### Choices in Psoriasis – Triggered by Failure or Motivated by Outcomes?

Chair Dr David Burden, Glasgow

13:15 **Introduction**  
Dr David Burden (Glasgow)

13:20 **The cumulative impact of psoriasis as a trigger for treatment**  
Professor Jemec (Denmark) TBC

13:35 **Interactive case study of the psoriasis patient treatment pathway**  
Dr Ruth Murphy (Nottingham)

14:05 **Questions**  
Dr David Burden, Professor Jemec & Dr Ruth Murphy

14:15 Close



# WEDNESDAY JULY 7TH – SATELLITE SYMPOSIUM

| TIME          | PROGRAMME                        | VENUE         |
|---------------|----------------------------------|---------------|
| 13:15 – 14:15 | JANSSEN CILAG SATELLITE SYMPOSIA | EXCHANGE HALL |

## Biologics in Psoriasis: Putting the Pharmacological Puzzle Together

Chair Professor Chris Griffiths, Manchester

Presentation 1 **The half life of biologics: what does this mean in clinical practice**

Co-Presenters:  
 Prof. Kristian Reich, Hamburg, Germany  
 and  
 Dr Hugh Davis, Centocor USA

Presentation 2 **The clinical impact of IL-12/IL-23 blockade in psoriasis: 3 year safety and efficacy update for ustekinumab treatment**  
 Dr David Burden, Glasgow

# WEDNESDAY JULY 7TH – SATELLITE SYMPOSIUM

| TIME          | PROGRAMME                         | VENUE           |
|---------------|-----------------------------------|-----------------|
| 13:15 – 14:15 | LA ROCHE-POSAY SATELLITE SYMPOSIA | CHARTER 3, 4, 5 |

## Optimising UVA Photoprotection

Moderator Prof. John Hawk, London

13:15-13:18 **Welcome & Introduction**  
 Prof. John Hawk, London

13:18 – 13:35 **Ultraviolet Radiation Effects on Skin**  
 Dr Henry Lim, Detroit

13:35 – 13:50 **The Need for Skin UVA Photoprotection**  
 Dr. Gillian Murphy, Dublin

13:50 – 14:05 **Ultimate UVA Photoprotection for the Photodermatoses**  
 Dr André Rougier, Paris

14:05 – 14:15 **Panel Discussion with Audience Participation**  
 Prof. John Hawk, Dr Henry Lim, Dr Gillian Murphy, Dr André Rougier

**Summary and Conclusions**  
 Prof. John Hawk, London

# THURSDAY JULY 8TH – SATELLITE SYMPOSIUM

| TIME          | PROGRAMME                          | VENUE         |
|---------------|------------------------------------|---------------|
| 13:15 – 14:15 | SCHERING-PLOUGH SATELLITE SYMPOSIA | EXCHANGE HALL |

**“This house believes we can manage psoriasis without using biologics.”**

Join the debate

Introduction  
and Chair

Jon Snow  
Veteran journalist and broadcaster

4 key speakers in the debate faculty will then present compelling arguments for and against the motion, with up-to-date reflections on the management of psoriasis as they see it:

**1st Proposer**

Professor Chris Griffiths, Manchester

**1st Opposer**

Professor Jonathan Barker, London

**2nd Proposer**

Dr Brian Kirby, Dublin

**2nd Opposer**

Dr David Burden, Glasgow

# MAP OF MANCHESTER



**Key:**

- 1 Manchester Central Convention Complex
- 2 Town hall: Annual dinner venue
- 3 Bar 38: Trainee / DermSchool evening venue
- 4 Barbirolli restaurant: SAS evening venue
- 5 Manchester Art Gallery: BSDS dinner venue
- 6 Room Restaurant: President's Private dinner venue

## CES MEETINGS CALENDAR

### SEPTEMBER 2010

#### **Learning Teaching & Assessment Course**

Venue: BAD House

Date: 1st – 2nd September

#### **Dermdoc**

Venue: BAD House

Date: 20th September

#### **SpR Training Event**

Venue: BAD House

Date: 30th September – 1st October

### OCTOBER 2010

#### **Management of Non-Melanoma Skin Cancer in the UK**

Venue: The Royal Society of Medicine

Date: 8th October

### NOVEMBER 2010

#### **Clinical Dermatology Update Meeting for Staff and Associate Specialist Doctors**

Venue: Radisson SAS, Manchester

Date: 4th – 5th November

#### **The Annual UK Dermatology Course for Consultants**

Venue: The Hilton Paddington Hotel, London

Date: 26th – 27th November

For Further Details on any of these meetings please contact:

- **Conference & Event Services;**  
4 Fitzroy Square  
London  
W1T 5HQ
- **Email:** [conference@bad.org.uk](mailto:conference@bad.org.uk)
- **Tel:** 020 7391 6358







# NOTES

A large area of horizontal blue lines provided for writing notes.

EVEN WHEN SKIN IS FLARE-FREE ON THE SURFACE

ECZEMA IS ALWAYS WAITING TO ATTACK

**FOR LONG-TERM ECZEMA CONTROL  
YOU NEED TO ACTIVELY MANAGE THE UNDERLYING INFLAMMATION.<sup>1</sup>**

Atopic eczema flares can be managed in the short-term, but the threat of another flare is always lurking under the surface. New twice-weekly Protopic offers an effective way to control eczema in the long-term by treating the sub-clinical inflammation between flares.<sup>2</sup> It prevents flares and prolongs flare-free intervals in adults and children with moderate to severe eczema.<sup>2</sup>

**SO DON'T WAIT FOR THE FLARE, USE TWICE-WEEKLY PROTOPIC  
TO CONTROL MODERATE TO SEVERE ECZEMA IN THE LONG TERM.\***

\*Patients should have had an initial response to an acute exacerbation with Protopic twice daily (max. 6 weeks' treatment).



**Protopic®**  
(tacrolimus 0.03%, 0.1% ointment)

*Twice weekly for long-term eczema control\**

**REFERENCES:** 1. Leung DYM et al. *J Clin Invest* 2004; 113(5): 651-657. 2. Protopic Summary of Product Characteristics, 2009. **PRESCRIBING INFORMATION:** Protopic® 0.03% ointment (tacrolimus monohydrate) Protopic® 0.1% ointment (tacrolimus monohydrate) **ACTIVE INGREDIENT** Protopic® 0.03% ointment (1g) contains 0.3mg of tacrolimus as tacrolimus monohydrate (0.03%). Protopic® 0.1% ointment (1g) contains 1.0mg of tacrolimus as tacrolimus monohydrate (0.1%). **THERAPEUTIC INDICATIONS** Protopic® 0.03%: treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. Protopic® 0.1%: - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. Protopic® 0.03%, 0.1%: maintenance treatment of moderate to severe atopic dermatitis for prevention of flares and prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected). **DOSAGE AND METHOD OF USE** Protopic® should be initiated by physicians with experience in the diagnosis and treatment of atopic dermatitis. Protopic® can be used for short-term and intermittent long-term treatment. Treatment should not be continuous. Protopic® should be applied as a thin layer to affected or commonly affected areas of the skin and may be used on any part of the body, including face, neck and flexure areas (except eyes and mucous membranes). Protopic® should not be applied under occlusion. Protopic® is not recommended for use in children below the age of 2 years until further data are available. Specific studies have not been conducted in elderly patients. However clinical experience has not shown the necessity for any dosage adjustment. **Treatment of flares:** Protopic® treatment should begin at the first appearance of signs and symptoms. Each affected region of the skin should be treated with Protopic® until lesions are cleared, almost cleared or mildly affected. Thereafter, patients are considered suitable for maintenance treatment (see below). At the first signs of recurrence (flares) of the disease symptoms, treatment should be re-initiated. **General considerations for treatment of flares:** Use in children (2 years of age and above) Protopic® 0.1% is not indicated for use in children. Treatment with Protopic® 0.03% should be started twice a day for up to three weeks. Afterwards the frequency of application should be reduced to once a day until clearance of the lesion. Use in adults (16 years of age and above) Treatment should be started with Protopic® 0.1% twice a day and continued until clearance of the lesion. If symptoms recur, twice daily treatment with Protopic® 0.1% should be restarted. An attempt should be made to reduce the frequency of application or use the lower strength if the clinical condition allows. Generally, improvement is seen within one week of starting treatment. If no signs of improvement are seen after two weeks of treatment, further treatment options should be considered. **Maintenance of flare-free intervals:**

Protopic® should be applied once a day twice weekly (e.g. Monday and Thursday) to commonly affected areas to prevent progression to flares. Between applications there should be 2-3 days without Protopic® treatment. Adult patients (16 years of age and above) should use Protopic® 0.1%, children (2 years of age and above) should use the lower strength Protopic® 0.03%. If signs of a flare reoccur, twice daily treatment should be reinitiated. After 12 months, a review of the patient's condition should be conducted by the physician and a decision taken whether to continue maintenance treatment. In children, this review should include suspension of treatment to assess the need to continue this regimen and to evaluate the course of the disease. **UNDESIRABLE EFFECTS** Very common: Burning sensation (which tends to resolve within one week of starting treatment), pruritus. Common: Sensation of warmth, erythema, pain, irritation, paraesthesia and rash at site of application. Alcohol intolerance (facial flushing or skin irritation after consumption of an alcoholic beverage). Patients may be at an increased risk of herpes viral infections (herpes simplex [cold sores], eczema herpeticum, Kaposi's varicelliform eruption) and folliculitis. Uncommon: acne. During post-marketing experience: Rosacea. Also, cases of malignancies, including cutaneous and other types of lymphoma, and skin cancers, have been reported in patients using tacrolimus ointment. Application site impetigo and application site infections occurred more frequently in a study of maintenance treatment in adults and children. Prescribers should consult the summary of product characteristics in relation to other side effects. **PRECAUTIONS FOR USE** Protopic® should not be used in patients with congenital or acquired immunodeficiencies or in patients on therapy that causes immunosuppression. The effect of treatment with Protopic® on the developing immune system of children, especially the young, has not yet been established and this should be taken into account when prescribing to this age group. Exposure of the skin to sunlight should be minimised and the use of ultraviolet (UV) light from a solarium, therapy with UVB or UVA in combination with psoralens (PUVA) should be avoided during use of Protopic®. Patients should be advised on appropriate sun protection methods, such as minimisation of the time in the sun, use of a sunscreen product and covering of the skin with appropriate clothing. Protopic® ointment should not be applied to lesions that are considered to be potentially malignant or pre-malignant. Emollients should not be applied to the same area within 2 hours of applying Protopic®. Concomitant use of other topical preparations has not been assessed. There is no experience with concomitant use of systemic steroids or immunosuppressive agents. Before commencing treatment with Protopic®, clinical infections at treatment sites should be cleared. The potential for local immunosuppression (possibly resulting in infections or cutaneous malignancies) in the long term (i.e. over a period of years) is unknown. Protopic® contains the active substance tacrolimus, a calcineurin inhibitor. In transplant patients, prolonged systemic exposure to intense immunosuppression following systemic administration of calcineurin inhibitors has been associated with an increased risk of developing lymphomas and skin malignancies. In patients using tacrolimus ointment, cases of malignancies, including cutaneous and other types of lymphoma, and skin cancers have

been reported. Patients with atopic dermatitis treated with Protopic® have not been found to have significant systemic tacrolimus levels. Lymphadenopathy was uncommonly (0.8%) reported in clinical trials. The majority of these cases related to infections (skin, respiratory tract, tooth) and resolved with appropriate antibiotic therapy. Patients who receive Protopic® and who develop lymphadenopathy should be monitored to ensure that the lymphadenopathy resolves. Lymphadenopathy present at initiation of therapy should be investigated and kept under review. In case of persistent lymphadenopathy, the aetiology of the lymphadenopathy should be investigated. In the absence of a clear aetiology for the lymphadenopathy or in the presence of acute infectious mononucleosis, discontinuation of Protopic® should be considered. Protopic® should be used with caution in patients with hepatic failure. Protopic® should not be used in patients with Netherton's syndrome. Care should be exercised if applying Protopic® to patients with extensive skin involvement over an extended period of time, especially in children. The development of any new change different from previous eczema within a treated area should be reviewed by the physician. Protopic® should not be used during pregnancy unless clearly necessary and is not recommended when breast-feeding. The safety of Protopic® has not been established in patients with generalised erythroderma. Protopic® is unlikely to have an effect on the ability to drive or use machines. **CONTRAINDICATIONS** Hypersensitivity to macrolides in general, to tacrolimus or to any of the excipients. **INTERACTIONS** Because of the potential risk of vaccination failure, vaccination should be administered prior to commencement of treatment, or during a treatment-free interval with a period of 14 days between the last application of Protopic® and the vaccination. In case of live attenuated vaccination, this period should be extended to 28 days or the use of alternative vaccines should be considered. Systemically available tacrolimus is metabolised via the hepatic Cytochrome P450 3A4. The possibility of interactions cannot be ruled out and the concomitant systemic administration of known CYP3A4 inhibitors in patients with widespread and/or erythrodermic disease should be done with caution. **PACKAGE SIZES** Prices exclude VAT: Protopic® 0.03% ointment £19.44 (30g tube), £35.46 (60g tube) Protopic® 0.1% ointment £21.60 (30g tube), £39.40 (60g tube) **LEGAL CATEGORY:** POM. **MARKETING AUTHORISATION NUMBERS** Protopic® 0.03% ointment EU/1/02/201/001-2 Protopic® 0.1% ointment EU/1/02/201/003-4. **FURTHER INFORMATION AVAILABLE FROM:** Astellas Pharma Ltd, Lovett House, Lovett Road, Staines, TW18 3AZ, UK. **DATE OF REVISION:** December 2009. **FOR FULL PRESCRIBING INFORMATION REFER TO THE SUMMARY OF PRODUCT CHARACTERISTICS.**

Adverse events should be reported. Reporting forms and information can be found at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk). Adverse events should also be reported to Astellas Pharma Ltd - 0800 783 5018

# Golf Day at the Belfry

Friday 1st October 2010

## Fancy a round of golf?

The British Skin Foundation is looking for keen individuals who like the idea of swinging for a great cause.

Register now for 'Swing for Skin', a fantastic opportunity to play at the world renowned Belfry golf course in the West Midlands and a great way to support the only charity in the UK dedicated to fundraising for skin disease research.

Play at the 18 holes of the **Brabazon course** and the driving range are included in the price as is a buffet dinner.

There will also be complimentary longest drive and nearest the pin competitions on the day. The event promises to be a huge amount of fun and a fantastic competition!

**Sign up now, spaces are limited!**

Start time: 10.30am - 1.20pm (depending on tee off time)

To register, or for more information, call the BSF events team on **0207 391 6352** email [bsfevents@bad.org.uk](mailto:bsfevents@bad.org.uk) or visit [www.britishskinfoundation.org.uk](http://www.britishskinfoundation.org.uk)



Registered Charity No. 313865